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1 
Introduction 
 
1. Pancreas: Histology 
The pancreas is a compound gland of the digestive system that consists of several 
functionally and morphologically distinct cell populations derived from the endoderm.  
The exocrine part represents 95-99% of the total pancreatic mass. It consists of:                  
- acinar cells, arranged into clusters at the end of the ducts, that produce digestive 
enzymes (amylase, lipase, phospholipase) as well as pro-enzymes (elastase, 
procarboxypeptidase, trypsinogen, pepsinogen, deoxyribonuclease, ribonuclease), 
which are stored in zymogen granules located in their apical pole;  
- dutal cells, which secrete mucus, chloride and bicarbonate, and compose the 
complex tubular system that drains acinar secretions to the to the duodenum, for the 
intestinal digestion of nutrients.  
The endocrine compartment is organized in islets of Langerhans scattered within the 
exocrine tissue, representing 1-5% of the pancreatic mass. Adult islets are composed 
of different cell types characterized by the production of specific hormones: the 
glucagon-secreting α-cell, insulin-secreting β-cell, somatostatin-releasing δ-cell, 
ghrelin-producing  ε -cell, and finally the pancreatic polypeptide-secreting PP-cells. 
Insulin and glucagon control blood glucose levels, whereas PP and ghrelin are 
orexigenic hormones and somatostatin regulates the secretion of insulin, glucagon 
and PP (Fig.1). 
The endocrine cells aggregate to form the islets of Langerhans, which are 
intermingled with blood vessels, neurons, and a mesodermally-derived stromal 
component. The intimate interaction between endocrine and vascular cells regulates 
hormone release, establishing a fine-tuned glucose homeostasis in the body [1]. 
 
 
 
Introduction 
 
 
 
 
2 
 
                                   Fig.1 A pancreatic islet embedded in exocrine tissue. 
 
2. Mouse pancreatic development   
 
2.1 Pre-pancreatic endoderm patterning 
During embryonic development, from the inner cell mass (ICM) of the blastocyst will 
develop the epiblast which undergoes gastrulation and forms the three principal germ 
layers: the ectoderm, which forms the skin and central nervous system; the 
mesoderm which forms the blood, heart and bones and the endoderm which forms 
the respiratory and digestive system [2]. The first sign of gastrulation is the formation 
of the primitive streak (PS) at day E5.5. It is characterized as a furrow in which 
epiblast cells will go on to form the mesoderm and endoderm through an epithelial-to-
mesenchymal transition (EMT) [3]. Nodal, a member of the transforming growth 
factor-beta (TGF) family, promotes mesoderm and endoderm formation [4,5]. The 
Wnt signalling pathway is involved in the mesoderm versus endoderm cell fate 
choice; indeed, embryos lacking -catenin, a key effector of the canonical Wnt 
pathway, have ectopic mesoderm cells in the endoderm germ layer [6]. 
In mouse, the transcription factors involved in endoderm formation, that act 
downstream of the Nodal and Wnt signals are: Mixl1 [7], Foxa2 [8], Goosecoid (Gsc) 
[9], Gata4 [10] and Sox17 [11].  
In the mouse embryo at E7.5, the structure of the endoderm, consisting of 500-1000 
cells, surrounds the mesoderm and ectoderm. At E8.5 the primordial epithelium of 
the primitive gut tube originates from the definitive endoderm, that is divided in three 
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parts along the anterior-posterior axis (A-P): the foregut, the midgut and the hindgut. 
The evaginations arising from these different domains of the foregut will give rise to 
organs, such as the thyroid, lung, liver, and pancreas [12,13]. Fibroblast growth 
factor (FGF) [14], Wnt [15], Hedgehog (Hh) [16] and Retinoic acid (RA) [17,18,19] 
signalling pathways have been implicated in formation and patterning of the foregut.  
There are reports that FGF4 suppresses the expression of Nkx2.1 and Hhex, which 
are required for foregut endoderm formation, and it promotes the expression of Pdx1 
and Cdx1/Cdx2.  
In Xenopus embryos, Wnt/β-catenin activity must be suppressed in anterior 
endoderm to maintain foregut identity and to allow liver and pancreas development, 
whereas high Wnt/ β-catenin activity in the posterior endoderm promotes intestinal 
fate. 
RA promotes pancreas organ allocation; indeed, blocking RA signaling inhibits 
pancreas specification. In Raldh2 null mice, which lack a critical RA-synthesizing 
enzyme, the dorsal pancreas fails to bud and the early glucagon-positive cells do not 
develop. RA is also required to maintain the pancreatic progenitors and to promote 
the commitment of these progenitors to Ngn3-positive endocrine progenitors [20,21]. 
 
2.2 Dorsal pancreas induction 
At E8.0, inductive signals (RA) from the paraxial mesoderm, together with 
suppression of Shh in the dorsal endoderm by FGF2 and Activin 2 from the 
notochord, are required to establish the dorsal pre-pancreatic domain. At first the 
inhibition of Shh is  required for early pancreas specification, after its activity is 
needed to expand the pancreatic epithelium and to regulate the expression of insulin 
in the mature -cells [22,23]. 
At 8.5, VEGF produced in the early dorsal aorta and vitelline veins induces the initial 
stages of pancreas development; it promotes the expression of Pdx1 and Ptf1a in 
pre-pancreatic endoderm. In the absence of VEGF-A in the Pdx1-positive pancreatic 
epithelium, the endocrine cells signal back to the adjacent endothelium to induce a 
dense network of fenestrated capillaries within the islet [24,25]. 
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By E9.5, condensation of the dorsal mesenchyme results in the evagination of the 
dorsal pancreatic rudiment. FGF10 stimulates bud outgrowth and proliferation of the 
pancreatic progenitor pool, inducing expression of the Ptf1a [26]. 
 
2.3 Ventral pancreas induction 
The ventral endoderm forms ventral pancreatic endoderm receiving signals from 
cardiac mesoderm and the septum transversum mesenchyme (Fig. 2). Liver and 
ventral pancreas may diverge from an early common population of bipotential 
progenitors in the ventral foregut endoderm [27]. Probably, the ‘‘default fate’’ of 
ventral foregut endoderm is pancreas. In this way can be considered two aspects, 
the first is that the endodermal interaction with cardiac mesoderm is required for 
hepatic differentiation, and the second that the septum transversum mesenchyme 
produces BMPs that are necessary to induce a liver gene expression program and to 
allow some progenitor cells within a speciﬁc region of the ventral foregut endoderm to 
escape the pancreatic fate instruction.  
A tissue-migration morphogenetic process allows part of the ventral endoderm to 
avoid hepatic-inducing signals; in fact, locking the relative movement of the ventral 
lateral foregut endoderm (the prospective ventral pancreas) prevents ventral 
pancreas speciﬁcation from occurring. 
Recent studies demostrate a strong link between the extrahepatobiliary (EHB) 
system (including gall bladder primordium, extrahepatic bile duct, cystic duct) and the 
ventral pancreas, more than with the liver. Sox17, a major regulator of endoderm 
formation,  is required to establish and maintain distinct boundaries between the liver, 
EHB, and ventral pancreas domain. 
Loss of Sox17 function after gastrulation leads to biliary agenesis and ectopic 
pancreas formation, whereas Sox17 misexpression suppresses pancreas 
development by promoting ectopic biliary-like tissue within the posterior foregut 
region that expresses Pdx1. Sox17 upregulates Hes1 levels in Pdx1 expressing 
endoderm; Hes1 then establishes a negative feedback loop to restrict Sox17+ biliary 
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progenitors to the ventral foregut endoderm generating a boundary between EHB 
and ventral pancreas [28]. 
Later, as the gut tube forms, the prospective ventral pancreatic endoderm comes into 
contact with a pair of vitelline veins dorsal pancreatic mesenchyme is an important 
signalling tissue that allows proliferation and morphogenesis of pancreatic 
progenitors after the initial budding of the anlage. 
 
 
 
                            
 
 
 
 
Fig.2 Schematic view of a mouse embryo showing the positions of the specified  pancreas tissue 
domains. 
 
2.4 The primary transition 
In the mouse, pancreas development start at E9.0 when the dorsal foregut endoderm 
thickens and evaginates into the surrounding mesenchyme. This is followed at E9.5 
by the emergence of the ventral pancreas bud from the ventral foregut endoderm. 
This early pancreatic epithelium comprises mainly multipotent pancreatic progenitor 
cells (MPC) together with a few early-differentiated ‘‘ﬁrst wave’’ endocrine cells, 
which are mainly glucagon+, although short-lived insulin+ and glucagon+/insulin+ cells 
were reported [29].  
In the first developmental transition (E9.5–E12.5), the epithelium of the two buds 
undergoes branching morphogenesis, and the compartmentalization of the 
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pancreatic epithelium commences, defining the epithelium into distinct ‘‘tip’’ and 
‘‘trunk’’ domains. While the tip domains contain multipotential pancreatic cells (MPC), 
which are then believed to change into acinar-fated progenitors, the trunk domain 
consists of an endocrine-duct bipotential progenitor pool [30]. The 
comprtmentalization starting from a simple bud, the epithelium moves through a 
transient stratification. Tube formation starts at  E10.75 when apical polarization of 
single cells occurs stochastically in the bud. These polarized epithelial cells undergo 
dramatic cell shape changes and rearrangements, forming “epithelial rosettes” that 
rather rapidly produce proper lumens at their common apical surface. The 
microlumens expand and eventually fuse, converting the epithelium through a multi-
lumen intermediate into a complex epithelial network or plexus. Tubulogenesis sets 
up the initial tip (future acinar location) versus trunk compartmentalization. The 
progenitors that are in close proximity to the mesenchyme and receive a longer 
integrated exposure to extracellular matrix (ECM) acquire acinar fate, whereas 
progenitors receiving less mesenchyme exposure have a higher bias towards 
forming endocrine cells. At E12.0-E15.0, the tubular epithelial network expands and 
undergoes remodeling, generating the mature acinar and ductal cells. About the 
branching morphogenesis, it was proposed that ∼85% of branching in these early 
stages was via lateral branching mechanism, and only about 15% by terminal 
bifurcation [31]. The lateral branching seemed frequent near the extending tip 
epithelium, which could include cells that have substantial “retained MPC-like”, in 
fact, these cells retain expression of the “primary multipotency markers” Pdx1 and 
Ptf1a. The trunk epithelial domain, contains a pool of cells with duct/endocrine 
bipotency, scattered cells within the trunk epithelium upregulate Ngn3 expression 
and commit to becoming endocrine precursors, that subsequently delaminate from 
the epithelial cord during the secondary transition. The remaining non-delaminating 
HNF1β+ Sox9+ Nkx6.1+ trunk cells are fated to become duct cells. The resolution of 
Nkx6.1 and Ptf1a expression into exclusive trunk and tip compartments, respectively, 
appears to correlate with the progressive restriction of trunk and tip cells towards the 
future duct/endocrine (trunk), or acinar (tip) lineages. 
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The progenitor cells allocated to the pancreas primordium in the first wave of 
development determines the final size of the mature pancreas [32], this type of organ 
size control is distinct from the ‘‘regulative programs’’ seen in other organs (e.g., liver, 
blood, central nervous system), in which reduction of progenitor numbers can be 
compensated by extensive proliferation, reduced apoptosis, with substantial effects 
from extrinsic factors [33]. 
 
2.5 Transcriptional program 
As the buds grow, MPC progressively commit to the pancreas fate and move into a 
differentiated state and a high-proliferation, that reﬂects the expression of several 
TFs (transcription factors, Fig.3). 
Pdx1 is expressed at E8.5 in the dorsal and ventral endoderm regions that give rise 
to pancreatic buds, as well as in the common bile duct, distal stomach, Brunner’s 
glands, and duodenal epithelium.  Pdx1-expressing progenitors produce acini, ducts, 
and endocrine cells of the mature pancreas [34]. Pancreatic expression continues in 
the pancreatic epithelium and high level expression progressively becomes restricted 
to pancreatic β cells and a small subpopulation of δ and PP cells. Low levels are 
detected in acinar cells, it  is required for their formation and differentiation [35,36]. In 
acinar cells, the Pdx1-Pbx1-Meis2 trimeric complex cooperates with PTF1 to activate 
the acinar-specific elastase1 promoter [37].  
Furthermore, correct levels of Pdx1 expression are important for proper pancreas 
formation.  The precise regulation of Pdx1 levels within the various pancreatic cell 
types are affected largely by the conserved 5′ cis-regulatory elements. There are four 
highly conserved regions, termed Area I–II–III (the “proximal enhancer region”) and a 
more upstream Area IV (the “distal enhancer”) Areas I–II impart islet-
specific Pdx1 expression, while Area III working alone can confer β-cell-specific 
expression. Areas I–II–III harbor binding sites for many TFs such as HNF1α, Pdx1, 
Foxa2, Pax6, HNF6, and MafA.  
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Area IV and is required for expansion and differentiation of pancreatic progenitors 
while Area III binding is linked more to the differentiation and function of mature β-
cells [38].  
Dorsal pancreas development arrests after initial budding in Pdx1 null mutants, 
resulting in a highly abrogated, developmentally retarded tissue, and a “ventral 
pancreas rudiment” cannot be found [39]. 
Hlxb9 is expressed in the dorsal bud prior to the dorsal induction of Pdx1. Between 
E10.5 and E12.5, its expression declines in both buds, but later is expressed in 
mature β cells. Hb9 is an essential intrinsic signal for dorsal pancreas evagination as 
well as for initiation of the pancreatic program. 
In mice lacking Hlxb9, the dorsal pancreas is entirely absent, Pdx1 is not expressed, 
and the epithelium does not bud. The ventral pancreas, remarkably, develops 
normally until later stages. This may reflect an intrinsic difference between the dorsal 
and ventral buds, but because Hlxb9 is also expressed in the notochord, which is 
known to promote dorsal pancreas development [40], its role in pancreas 
development may be indirect. 
Ptf1a. The trimeric Pancreas Transcription Factor 1 complex (PTF1)  comprises a 
tissue-specific bHLH protein, Ptf1a, the distinct mammalian Suppressor of Hairless 
(RBP-J) protein, or the RBP-JL paralog. Ptf1a is expressed as early as E9.5 in most 
cells of the nascent pancreatic buds, and appears to play an important role in early 
specification of pancreatic progenitor cells and later, in regulating exocrine 
differentiation. Mice lacking the Ptf1a/p48 bHLH transcription factor exhibit normal 
dorsal bud formation, whereas the ventral pancreas not only fails to bud but becomes 
integrated into the surrounding duodenum. In addition to the complete lack of acinar 
cells, endocrine cell numbers are greatly reduced [41]. 
During early stages of organogenesis, the RBP-J form is required for pancreas 
specification and progenitor maintenance. PTF1-RBP-J complexes activate the 
expression of RBP-JL, and increased RBP-JL then begins to displace RBP-J, 
switching PTF1-RBP-J  to PTF1-RBP-JL  and initiating the acinar differentiation 
program [42]. It is interesting to notice that these events are concomitant with the lost 
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of multipotency of the Cpa1+ tip cells suggesting that the switch of Rbpj partner into 
the PTF1 complex may play a role in this specification into a single lineage.  
Sox9 is a member of the SRY/HMG box (Sox) family, is involved in the proliferation, 
survival, and maintenance of pancreatic progenitors. Sox9 expression is first 
detected at ∼E10.5 in the early pancreatic MPC, and lineage tracing revealed that the 
“first-wave” Sox9+ progenitors, like Pdx1+ and Ptf1a+ progenitors, produce cells of all 
three pancreatic lineages. In the adult pancreas, Sox9 expression is maintained in a 
duct epithelium subpopulation. The pancreas-specific Sox9 inactivation caused 
hypoplasia of both buds, through the decreased proliferation and increased cell death 
of progenitors, so it is essential in MPC proliferation and survival. Sox9 regulates the 
expression of several TF genes in the primary pancreatic MPC such 
as Onecut1/Hnf6, Tcf2/Hnf1β, Foxa2 and Ngn3 expression suggesting a role in 
initiation of endocrine differentiation [43]. 
Hnf1β  is expressed broadly through the foregut-midgut region at E8.0, and in the 
liver and both pancreas anlagens at E9.5. Hnf1β-expressing pool is multipotent and 
can seed all three compartments: acinar, duct, and endocrine. During the secondary 
transition, Hnf1β expression becomes confined to the duct/endocrine bipotent 
progenitor domain of the central epithelial cord. In the absence of Hnf1β, there is the 
transient formation of a dorsal pancreas bud that expresses Pdx1 and Mnx1, but 
these progenitors fail to expand; the ventral bud is absent [44]. In addition 
to Ptf1a, Hnf1β seems to form a transcription regulatory cascade with Hnf6 in 
controlling pancreatic progenitor generation and endocrine progenitor induction [45]. 
Gata4 and Gata6 are initially expressed broadly over the early foregut endoderm, 
and later in the pancreatic anlagen. During the secondary 
transition, Gata4 and Gata6 expression becomes uncoupled and restricted to distinct 
pancreatic domains. Gata4 expression is restricted to acini between E13.5-E18.5. In 
the adult pancreas, Gata4 is expressed in a subset of α and β-cells and is no longer 
detectable in acinar cells. Gata6 mRNA is detected in the bipotential central epithelial 
cord of the secondary transition. 
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In Gata4 nulls, the ventral pancreas is not specified while the dorsal pancreas bud 
forms essentially normally. Gata6 nulls exhibit a similar phenotype with a few 
detectable Pdx1+ ventral foregut cells compared to none in the Gata4 null [46]. 
Mnx1 is expressed at E8.0 within the notochord and the entire dorsal and ventral 
endoderm at the prospective pancreatic level, the expression remaining in both 
pancreatic buds and the stomach until E12.5, becoming confined to Pax6+ endocrine 
precursors during the secondary transition. In adult pancreas, Mnx1 is expressed in 
mature β-cells. 
Mnx1 expression in the dorsal pancreatic rudiment precedes Pdx1. Mnx1 null mice 
show dorsal bud agenesis and the normal Pdx1 upregulation during early bud 
formation does not occur. 
Mnx1 expression in the ventral pancreatic rudiment occours after Pdx1. In Mnx1 null 
mice, ventral pancreas development proceeds normally, producing all pancreatic cell 
types, but with increased δ-cells  and reduced β-cell numbers that are are immature 
in that they lack Pdx1, Nkx6.1, and Glut2 [47].  
Ngn3 is expressed exclusively in endocrine precursor cells, and subsequently down-
regulated during differentiation. Ngn3 promotes endocrine fate in cells descended 
from Pdx1 progenitor cells.  
Notch signaling has two major functions during the development of the pancreas: a 
role in the maintenance of early progenitor cell in an undifferentiated state and a role 
in lateral inhibition, allowing selection of endocrine cells between non-endocrine cells. 
Regarding the first function, Notch signaling appears to control directly and indirectly 
the expression of Ngn3. 
In the mechanism of lateral inhibition, Notch signaling inhibits the expression of 
Ngn3, leading to maintenance of the population of precursors, because preventing 
differentiation. This mechanism is triggered by the expression of Ngn3 in 
commissioned cells to differentiate, with the production of an extracellular ligand of 
Notch, Delta-like ligand 1 (Dll-1), which activates the NOTCH1 receptor in 
surrounding cells by cutting an intracellular domain of the receptor. This domain 
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interacts with RBP-J  activating the expression of Hes1, which inhibits the promoter 
of Ngn3 [48].  
Mice deficient for Notch signaling pathway components such as RBP-Jk, Dll1, or 
Hes1, display increased numbers of Ngn3-positive cells, premature endocrine 
differentiation and a hypoplastic pancreas that is likely the result of premature 
depletion of pancreatic precursor cells [49,50,51].  
Hes1 encodes a bHLH transcription factor, present in the pancreas from the day 
E9.5. It has been observed that the number of pancreatic endocrine cells in Hes1 null 
mouse  increases. So that Hes1 have a role in suppressing the development of 
endocrine cells through a pathway involving Notch. In Hes1 null mouse Ngn3 
expression is high both in stomach and in intestine, confirming the conflicting effect of 
Hes1 and Ngn3 on endocrine cells development. The reduced expression of Hes1 
could, therefore, facilitate the differentiation of pancreatic endocrine cells and this 
hypothesis was confirmed by conversion of the developing biliary system in the 
pancreatic tissue in Hes1 deficient mice [52].  
Hnf6 is expressed in the epithelial cells at the stage E9.5, and subsequently its 
expression becomes specific of the ductal and exocrine cells.  
Hnf6 mutant mice lack most Ngn3-expressing cells during development and instead 
accumulate primitive, undifferentiated epithelium; the block to endocrine 
differentiation in Hnf6 mutants is only temporary, and islets begin to bud out of the 
abnormal epithelium shortly after birth. 
Nkx2.2 is expressed early in developing pancreatic buds and is later restricted to α-, 
β-, and PP cells of islets. Nkx2.2 mutants completely lack insulin expression; in place 
of normal β-cells, islets contain a large population of cells apparently arrested of β-
cell fate.  
Nkx6.1 is expressed primarily in β-cells of adult islets. Nkx6.1 mutants have a 
phenotype with a small number of insulin-producing cells during early pancreatic 
development, the normally exponential increase in β-cell generation that initiates 
during the secondary transition is completely absent, and no immature β-like cells are 
formed. 
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Beta2/NeuroD1 is a key regulator of insulin gene transcription in pancreatic β-cells. 
Beta2/NeuroD expression occurs in a subset of pancreatic epithelial cells as early as 
E9.5, co-localizing with glucagon expression. On E14.5, expression appears within 
and in proximity to ductal epithelium, and by E17.5, expression is restricted to islets.  
Mice homozygous for a targeted disruption of the Beta2/NeuroD gene survive to 
birth, but die within 3–5 days post partum of severe hyperglycemia. The islets of 
these mice are dysmorphic and have markedly diminished numbers of endocrine 
cells arranged in streaks and irregular. 
Pax4 is expressed at E9.5 in both ventral and dorsal buds of the developing 
pancreas, and by the time of birth, expression is restricted to β-cells. The Pax4-null 
mice survive birth, but die within 3 days of hyperglycemia and dehydration. There is a 
virtual absence of β- and δ-cells, but α-cells are increased. Pdx1 expression in Pax4-
null pancreas is absent, a finding consistent with the absence of differentiated β-cells. 
Thus, Pax4 functions early in the development of islet cells to promote the 
differentiation of β- and δ-cells. 
Pax6 is expressed early in the epithelium of the developing pancreas on E9.0 in both 
dorsal and ventral pancreatic buds and is expressed in differentiated α-, β-, δ-, and 
PP cells. Knockout Pax6 mouse dies within minutes of birth. These animals fail to 
form islets. The disorganization of islets is proposed to relate to a possible function of 
Pax6 in the regulation of cell adhesion molecules.  
Brn4 (Pou3f4) regulates the promoter of the glucagon. Its expression begins in the 
pancreas at E10.0, prior to that of Pax6, which is believed to be the first gene that is 
expressed specifically in glucagon-positive cells of the pancreas. However, the 
defective mice to Brn4 develop normally the endocrine portion, so that the expression 
of this gene is considered not necessary to determine the fate of glucagon-positive 
cells [53]. 
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Fig.3 Flow of transcription factors during pancreatic development. 
 
2.6 Signalling pathways involved in pancreatic development 
The default fate of embryonic pancreatic epithelium is endocrine, and that this fate is 
redirected by mesenchymal signals to allow production of exocrine fates.  
During early stages (E9.5), the fibroblast growth factor receptor 2b (Fgfr2b) 
expression is detected in the epithelium, and its high affinity ligand Fgf10 is 
expressed in the pancreatic mesenchyme.  Transgenic mice expressing dominant-
negative Fgfr2b under the inducible metallothionein promoter, or mutants that lack 
either Fgf10 or Fgfr2b, display pancreatic hypoplasia [54,55], while, excess FGF10 
signaling leads to sustained Notch activation and promotes proliferation at the 
progenitor state [56,57]. 
Mesenchyme-derived BMP4/7, which signals through the epithelial ALK3 receptor, is 
also critical for pancreatic epithelium expansion and branching morphogenesis in 
mouse and chick. Inhibiting BMP signaling, either by over-expression of Noggin or a 
dominant-negative BMP receptor (dnALK3), causes severe pancreas hypoplasia, 
reduced epithelial branching, and excessive endocrine differentiation [58]. 
Isl1 plays a pancreas development-promoting role, both as an extrinsic factor 
produced by the dorsal mesenchyme, and intrinsically expressed in pancreatic 
progenitors. Targeted disruption of Isl1 renders the mesenchyme unable to condense 
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around the dorsal pancreatic bud. In absence of Isl1, no endocrine cells differentiate. 
In addition, exocrine cells appear only in the ventral bud.  
The activin-follistatin system plays an important role in the intrinsic regulation of 
pancreatic branching morphogenesis and for the determination between exocrine 
and endocrine balance. Activins are expressed in early gut endoderm, and also in 
early pancreatic rudiment and then localize to the developing endocrine pancreas 
[59]. Inversely, Follistatin, an activin-binding protein that acts as an antagonist, is 
expressed by early pancreatic mesenchyme [60]. Exogenous activin profoundly 
alters epithelial branching morphogenesis; it causes severe disruption of normal 
lobulation patterns in vitro whereas Follistatin counteracts its effect [61].  
 
2.7 The secondary and third transition 
Between E13 and E14, the dorsal and ventral pancreata rotate and fuse into a single 
organ (Fig.4). During E14.5 and E15.5, the exocrine pancreas differentiates from the 
ductal epithelium; at E15.5, acinar cells arise from the extending tip epithelium and 
continue to undergo active proliferation to increase the number of acinar tips by 
duplication processes acini are clearly discernible from ducts. Endocrine cells are 
present from the very beginning of development (E9.5), but up until E14.0 they are 
arrayed as single cells within the ductal epithelium, after which they undergo 
extensive proliferation (second developmental transition).  
In general, the first endocrine cells to form mature cells are α cells, Gcg-positive 
cells, followed by β cells (E13.5), the δ cells (E15.5) and finally PP cells (E17.0). 
Once differentiated, endocrine cells leave the epithelium and migrate to the 
extracellular matrix, thought an epithelial-to-mesenchymal transition (EMT) where 
they recognize and are aggregated to form the islet of Langerhans [62]. This cluster 
of endocrine cells and the subsequent formation of the islet is realized (E18.5) just 
before the birth (third developmental transition).  
In the mouse, predominantly -cells form the islet core, and they are surrounded by 
mantle of α, δ, and PP-cells, whereas the very minor ε-cell population is dispersed 
throughout the islet. About 80% of the islet cell mass present at birth is generated by 
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the proliferation and differentiation of endocrine progenitors, with the other 20% 
coming from islet cell proliferation [63]. After birth, the predominant mechanism for 
islet cell mass maintenance is self-duplication. There is a shorter refractory period for 
-cell proliferation observed in the first four weeks postnatally and a longer refractory 
period after weaning. 
 
Fig.4 Schematic representation of pancreas development in mice with an 
indication of the main  transcription factors involved. 
 
2.8 Endocrine specification 
The current model of ductal and endocrine cell fate segregation considers Notch-
regulated lateral inhibition, so the endocrine progenitors expressing Ngn3 
autonomously induce the production of Notch ligands, which signal to neighboring 
cells and activate Hes1 expression. Hes1 in turn suppresses Ngn3 expression, and, 
thus, inhibits endocrine fate acquisition in the neighbors. Ngn3 initiates the endocrine 
developmental program by inducing pro-endocrine TFs and factors involved in 
delamination of the pro-endocrine cells from the epithelium. The direct targets of 
Ngn3 include NeuroD1/Beta2, Pax4, Arx, Insm1, Rfx6, Nkx2.2, Myt1, andSnail2/Slug. 
Ngn3 activation in a limited number of cells within the trunk epithelium to take input 
from TFs such as Sox9, Hnf1β, Hnf6, Hnf3β, and Pdx1. Mice lacking Ngn3 function 
fail to develop endocrine cells [64], whereas ectopic Ngn3 expression under the Pdx1 
promoter induces premature differentiation of the entire pancreatic bud progenitor 
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pool into endocrine cells with predominantly α-cells. Lineage tracing studies showed 
that all endocrine cell types seem to be born from Ngn3-expressing endocrine 
progenitors. The inducible Ngn3 expression under the control of the Pdx1 promoter in 
the Ngn3 null background, to demonstrate that early Ngn3+ progenitors (E8.75) 
produce α-cells, whereas endocrine progenitors acquire the competence to make β-
cells and PP cells at ∼E11.5 and E12.5, respectively, with much increased 
competence towards the β-cell fate at E14.5. Endocrine progenitors become 
competent to produce δ-cells at E14.5. 
Three classes of endocrine regulators may be divided, based upon our current 
understanding of the phenotype: 
- general endocrine differentiation (NeuroD1, Islet1, Insm-1, Rfx6, Nkx6.1). 
NeuroD mutant mice have arrested endocrine cell development during the secondary 
transition, with reduced numbers of all endocrine cell types. The remaining endocrine 
cells fail to form islets [65]. Such deficiencies are also observed in Insulinoma-
associated antigen 1 (Insm1), Regulatory X-box binding 6 (Rfx6), and Islet1 (Isl1) 
mutants.  
Nkx6 family TF genes (Nkx6.1 and Nkx6.2) could be the only non-Ngn3 direct target 
that fall into this class. The Nkx6.1 null has substantially reduced β-cell numbers 
while both β and α-cells are reduced in Nkx6.1/Nkx6.2 double null mice, 
demonstrating an intriguing overlapping yet distinct requirement for the different Nkx6 
TFs. The number of Ngn3  endocrine progenitors and islet precursors are reduced 
dramatically in these mutants, suggesting that Nkx6 might act upstream of Ngn3. 
These studies also proposed that Nkx6 factors promote β-cell fate specification from 
Pdx1 progenitors and that Ngn3 subsequently promotes cell differentiation by 
initiating cell cycle exit. 
- lineage-allocation (Pdx1, Pax4, Arx, Nkx2.2).  
Lineage-specific factors control the flux of endocrine progenitors towards a specific 
endocrine type. As a consequence of removing factors such as Nkx2.2, Pax4, Arx, 
and Pdx1, endocrine cell numbers are largely unaffected, but fractional islet 
allocations are often severely altered. In Pax4 null mice, β and δ-cells are lost 
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concomitant with a remarkable increase in α-cell and ghrelin+ ε-cell numbers. The 
increased ε-cell number is similar to the Nkx2.2 null pancreas, suggesting possible 
genetic interactions between Pax4 and Nkx2.2. 
Pax4 and Arx induce, respectively, either an α-to-β or β-to-α conversion upon 
misexpression in terminally differentiated mature endocrine cell types. Thus, Pax4 
and Arx are required for β and α-cell fate allocation, respectively. Although Pax4 null 
mice also lack somatostatin+ δ-cells, a positive selective role for Pax4 in δ-cell 
development remains unclear. In addition, Pax4/Arx double null mice show a 
massive increase in δ-cells, which suggests that δ-cell terminal differentiation 
requires the absence of Pax4 and Arx [66]. 
Pdx1, apart from its early roles in MPC outgrowth and expansion, is also required for 
β-cell proliferation and survival. Deleting Pdx1 function specifically in β-cells leads to 
a dramatic reduction in β-cell number concomitant with α/δ-cell overgrowth.  
- maturation factors (MafA, MafB, Foxa1, Foxa2, NeuroD1).  
Loss of these factors causes little or no defect during endocrine cell lineage 
diversification, but the cells begin to show aberrant function postnatally or in 
adulthood. During development, β-cells move from a MafB+ immature state to 
MafA+/MafB+, and finally, to a MafA+ mature state. Thus, MafB is essentially absent 
from mature adult β-cells and its expression is restricted to α-cells in the adult 
pancreas. MafA mutants have no effect on endocrine cell development but the mice 
become glucose-intolerant postnatally [67]. MafB−/− mice have reduced α and β-cell 
numbers, as well as some form of apparently delayed β-cell development [68]. 
Conditional inactivation of Foxa2 (Foxa2-cKO) in early pancreatic epithelial 
precursors does not affect MPC development but leads to late-arising defects in α-
cell terminal differentiation. Initial specification of α-cells in the Foxa2-cKO proceeds 
normally but differentiation is blocked with 90% reduction of glucagon expression and 
complete lack of prohormone convertase 2 (PC2) production in these mutant mice. 
The resultant neonatal Foxa2 mutants die shortly after birth from severe 
hyperinsulinemic hypoglycemia.  
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 Deleting N-cadherin in the Pdx1 expression territory results in reduced insulin 
granules and impaired insulin secretion in β-cells. This suggests that cell adhesion or 
perhaps coordinated β-cell communication amongst the population is critical for 
proper regulation of insulin granule turnover. 
The NeuroD1 null islets responded poorly to glucose and displayed a glucose 
metabolism profile similar to immature β-cells. Therefore, NeuroD1 is required for the 
complete transition to β-cell maturity, and maintenance of full glucose-
responsiveness [69].  
Some of the TF mutants show more than one phenotype, suggesting multiple 
functions during endocrine development. 
 
2.9 Exocrine development 
The mature ductal network has four subcompartments:  a main duct as the common 
conduit to the duodenum; the interlobular ducts connected to the main duct; 
intralobular ducts draining exocrine enzymes into the interlobular ducts; intercalated 
ducts, also called terminal ducts or centroacinar cells (CAC), which connect the acini 
with intralobular ducts. Extensively abnormal duct development was reported in both 
global and pancreas-specific Hnf6 gene inactivation [70], although these duct defects 
are likely relatively directly connected to an earlier problem in the development and 
maturation of the secondary transition trunk epithelium, and not in the differentiation 
program of duct cells. Indeed, the cells in the “duct epithelial” tissue of the secondary 
transition trunk epithelium transiently represents a bipotent pool of endocrine and 
duct-competent progenitors. Deleting Pdx1 function at progressively later stages 
using an on-off doxycycline-regulated transgenic/knock-in system allows formation of 
interlobular ducts first, followed by intralobular ducts. It is possible that the large 
cystic ducts formed in the Pdx1 and Ptf1 null mutants adopted a common bile duct or 
intestinal character, and thereby lost the competence and microenvironment to 
produce the proper numbers of second-wave endocrine cells, but this hypothesis 
remains to be tested. Acinar differentiation starts at the distal tip epithelium at around 
E13.5. At this stage, the tip MPC undergo a switch to the pro-acinar fate by down-
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regulating sets of progenitor-specific TFs that maintain MPC status, while 
upregulating expression of Ptf1a and various digestive enzymes [71]. In comparison 
to endocrine development, fewer transcription factors have been shown to be 
involved in acinar development. Ptf1a is the key player in acinar formation; 
PTF1RBP-J switching to PTF1RBP-JL initiates the pro-acinar differentiation program 
during the secondary transitionits. The  loss of Ptf1a causes acinar agenesis. The 
PTF1RBP-JL complex can bind promoters of all the genes encoding secretory 
zymogens, including Amylase, Elastases 1 and 2, CpaI, chymotrypsin B, trypsin. 
Mist1, a bHLH factor, is required to establish proper apical-basal polarity and full 
acinar differentiation. Initiation of acinar development occurs in Mist1-deficient mice, 
suggesting action downstream of Ptf1a. However, acini in Mist1−/− mice do not 
acquire the typical rosette-like morphology, possibly as a consequence of loss of 
functional gap junctions that was attributed to reduced connexin-32 levels. To date, 
canonical Wnt signaling is the only reported extrinsic cue with direct implication on 
acinar development. Acinar differentiation fails early on in the absence of β-catenin 
[72]. 
 
3. Comparison between the human and mouse pancreas 
development 
Human pancreas formation largely mimics the process in the mouse. Dorsal and 
ventral pancreas budding is first evident at 26–35 dpc (day post coitum), and fusion 
of the anlagen occurs at 6 weeks of gestation (G6w, gestation 6 weeks). The dorsal 
bud produces most of the head, body, and tail of the mature pancreas, whereas the 
ventral bud contributes to the inferior part of the head of the organ [73]. 
The spatio-temporal patterns of key TFs suggest that similar transcriptional 
regulatory mechanisms operate in both human and mice. Pdx1 is found in pancreatic 
progenitors broadly through the epithelium from G7w, and later in insulin-producing 
cells. Ngn3+ cells are found scattered in the epithelium at G9w, concomitant with the 
emergence of β-cells first at G8w, which are followed by α-cells and δ-cells at G9w. A 
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rare population (<5%) of insulin+/glucagon+ cells was also reported in the early 
human fetal pancreas.  
Islet-like clusters appear from approximately G11w in human pancreas, the 
aggregated insulin and glucagon-expressing cells in the human fetal islets (around 
G14–16w) seem to be arranged similarly to the mouse adult islet, with a β-cell core 
and peripheral mantle of α and δ-cells. However, at G19w, it is proposed that there is 
a transient separation of the peripheral α-cells and δ-cells, away from the β-cell core, 
to form homogeneously mono-hormone-producing clusters. Presumably, the mono-
hormone islets reintegrate amongst each other after G22w, and there is significant 
intermixing to generate the adult islet architecture [74].  
 
4. Injury-Induced Reprogramming 
Four main hypotheses were proposed for the origin of β-cells during the response to 
injury, including:  
- replication of pre-existing β-cells. Under normal physiological conditions, β-cell 
turnover is slow and decreases progressively with age. Upon injury, it appears that at 
least some β-cells can re-enter the cell cycle. Under partial pancreatectomy 
conditions, have demonstrated that duplication of pre-existing β-cells represents a 
predominant mechanism of generating new β-cells in normal pancreas and under 
injury response [75]. 
- neogenesis from duct epithelium. The adult pancreatic ductal cells could give rise to 
insulin-producing cells upon injury, as a neogenetic birth process. Pancreatic duct 
ligation (PDL) is an injury model that generates tissue damage and cellular 
responses similar to those in acute pancreatitis. Ngn3+ cells were induced in the duct 
epithelium after PDL, and thus identified a potential source of new endocrine cells in 
vivo. These Ngn3+ duct cells, upon isolation, could produce all endocrine cell types 
when cultured in Ngn3 null pancreatic bud explants in vitro [76].  
- acini-to-endocrine or acini-to-duct-to-endocrine transdifferentiation. Several in vitro 
acinar cell culture studies demonstrated a potential acinar to endocrine/duct 
conversion when treated with EGF, nicotinamide, or TGF-α [77]. Upon caerulein 
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treatment in vivo, acinar cells transiently dedifferentiate to a progenitor-like state, 
based on the observation of Pdx1, Foxa2, Sox9, and Hes1 positivity [78]. In this 
case, transient dedifferentiation of acinar cells is followed by acinar regeneration with 
no contribution of acinar lineage to ductal and endocrine lineages. 
- endocrine cell interconversion, for example, α-to-β cells. With the expression of the 
diphtheria toxin (DT) receptor and the administration  of the DT to achieve ∼99% β-
cell destruction, the α-cells move through a bihormonal glucagon+/insulin+ state on 
their way to generate authentic insulin+ β-cells [79]. 
 
5. In vitro differentiation of embryonic stem cells 
The most important characteristics of Embryonic stem cells (ESCs) include the 
capacity to self-renew and the potential to differentiate into all embryonic cell types, a 
potential termed pluripotency, under in vivo and in vitro conditions. High serum 
composition medium and the presence of the Leukemia Inhibitory Factor (LIF) are 
the most common method to maintain the undifferentiated state and the self renewal 
ability of the murine ESCs (mESCs)in culture. 
However, directed differentiation of ESCs toward specific cell lineages has proven to 
be a challenging task. This is in part because directed induction of a desired cell type 
has to be balanced with the inhibition of the formation of unwanted cell fates. These 
protocols have been based on the findings obtained from decades of developmental 
biology research that has outlined a cascade of signaling molecules and transcription 
factors that guide undifferentiated progenitor cells toward fully mature, functional 
cells.  
During in vitro differentiation, both murine and human ESCs recapitulate early stages 
of embryonic development [80]. 
 
5.1 Endoderm induction 
The first crucial step in the differentiation of ESCs toward the pancreatic lineage is 
the specification of DE.  
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In vivo, BMP4, Wnt and Nodal signallings were shown to be involved in both PS and 
mesendoderm formation. In ESC cultures, BMP4 and Wnt signalling induced the 
formation of a PS-like population. Then, incubation with Activin A a member of the 
TGFβ superfamily - induced a PS-like population and, depending on the strength of 
the signal, the subsequent formation of endoderm or mesoderm, as it occurs in vivo 
through Nodal signalling. 
Nevertheless, successful formation of DE by Activin A treatment is significantly 
affected by different parameters, such as contaminating constituents in culture media 
during Activin A application, Activin A concentration, time and duration of treatment, 
and differentiation models used. Serum at high level negatively influences endoderm 
induction by Activin A. Insulin/insulin-like growth factor (IGF) contained in FCS or 
KSR, respectively, were inhibiting the Activin A-dependent DE induction through 
activation of the phosphatidylinositol 3-kinase (PI3K) pathway [81]. It was established 
that concentrations higher than 30 ng/ml and up to 100 ng/ml are sufficient to induce 
DE in mESCs. 
In the differentiation studies the time and duration of Activin A application vary 
substantially and depend on the culture system used. 
Wnt3a was supplemented within the first days of Activin A treatment in order to 
increase the efficiency of mesendoderm specification and the synchrony of DE 
formation [82]. 
The formation of DE can be confirmed by testing for the up-regulation of endodermal 
markers, including Sox17, Foxa2, Gata4.  
 
5.2 Pancreatic specification 
The next desired step after the formation of primitive gut endoderm is the induction of 
pancreatic epithelium. Suppression of the activity of Shh, a member of the Hedgehog 
signaling pathway, is required for the initial specification of pancreatic buds in vivo. 
Hedgehog inhibition can be mimicked in cell culture via treatment with Cyclopamine 
(CYC), a cholesterol analog known to block the function of Smoothened, an essential 
element of the Hedgehog signaling cascade. Addition of CYC to the differentiation 
 
Introduction 
 
 
 
 
23 
media at this stage promotes the formation of pancreatic endoderm marked by the 
expression of Pdx1, the earliest marker of pancreatic epithelium, among a collection 
of other transcription factors important for pancreas organogenesis. All trans retinoic 
acid (RA) is added to promote the commitment of the Pdx1-positive pancreas 
progenitors toward the endocrine lineage over pancreatic exocrine cells. Later on, 
FGF signalling is implicated in the proliferation of the pancreatic progenitors at the 
expenses of differentiation [83].  
Accordingly, d’Amour et al. applied successfully in ESCs a combination of CYC with 
FGF10 and RA to direct DE induced by Activin A into the pancreatic lineages, 
showing once again that in vivo data can be reproduced in vitro.  
The combination of RA-CYC-FGF10 has been extensively applied in pancreatic 
differentiation protocols using variable concentrations of these molecules. For 
instance, FGF10 is usually used at 10 to 50 ng/ml, CYC at 0.25 to 2.5 µM and RA, 
between 0.1 and 2 µM. In addition, the timing for the pancreatic specification step 
varies between 2, 3, 4 or 6 days. 
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Aim of Thesis 
 
Cell therapy offers good prospects for the treatment of pancreatic diseases, for this 
reason more attention has been given to the pancreatic progenitor cells. Several 
studies show the improvement of differentiation of embryonic stem cells towards the 
definitive endoderm and pancreatic progenitors, but the identification of new 
molecular markers could further facilitate differentiation. 
The aim of this study is to find new molecular markers involved in pancreatic 
specification. Therefore, our efforts will be directed towards in vitro and in vivo 
assessment of signature genes that would target the specification formation of 
pancreatic progenitor cells .  
Our approach to  identify  in vivo pancreas progenitor cell markers will be based on 
the analysis of global gene expression profile of dorsal pancreatic buds isolated from 
E10.5 mouse embryos.  
There is a signiﬁcant gap in our knowledge on the endodermal players that act in the 
time window between the early stages of endoderm formation and the regionalized 
expression of the posterior-foregut/pancreas marker gene Pdx1. Development of 
more precise lineage-tracing tools allow a deeper focus on the functional delineation 
between stages and mechanisms of speciﬁcation, commitment, lineage allocation, 
and differentiation. 
In particular, conditional gene knockout strategy will be used to characterize spatio-
temporal function of the putative markers during  pancreatic specification. 
The study will be followed by in vitro characterization of a candidate during 
differentiation of embryonic stem cells into the pancreatic lineage. We  propose to 
develop a protocol based on the sequential activation of signaling pathways that 
recapitulate pancreatic development in vitro, through the definitive endoderm 
formation, the pancreatic specification. 
We aim to generate genetically modified ES cell line expressing the beta-
galactosidase under the promoter of the gene candidate to enable the stain and the 
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collection of the cell population that expresses the novel putative marker of 
pancreatic cell specification.  
In this way, we would like to characterize both the global molecular signature of those 
cells, and eventually evaluate their ability to repopulate a diseased and/or damaged 
pancreas after current transplantation procedures. 
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Materials and Methods 
 
1. Embryo dissection and embedding  
Embryos were collected at E10.5 from C57/Bl6 mice; midday on the day of vaginal 
plug appearance was considered E0.5. All animals employed for the experiments 
were used in accordance with regulations and guidelines of Italy and the European 
Union and were approved by the local ethical committee. After dissection in cold 
phosphate-buffered saline (PBS), embryos were treated with 30% sucrose overnight 
at 4°C. They were rinsed in PBS, placed in sterile cryomolds biopsy and embedded 
in OCT (Sakura). 
 
2. Immunofluorescence                                                            
8 μm thick frozen sections were collected on polylysine glass slides (Menzel-Gläser) 
and fixed with 4% paraformaldehyde (PFA) for 15 minutes. After, the sections were 
permeabilizated in 0.1% Triton X-100 in PBS (PBT) twice for 10 minutes and then 
fixed with 4% PFA for 5 minutes. The sections were pre-incubated in Protein block 
serum-free (DakoCytomation) at room temperature for 15 minutes. This product 
inhibits non-specific staining during the immunofluorescence detection of antigens. It 
may be especially useful when staining connective tissue, epithelial tissue, 
adipocytes, or other types of tissues susceptible to high background. The sections 
were incubated with primary antibodies monoclonal Rat anti-E-Cadherin 1:2500 
(ECCD-2, Calbiochem), Rabbit Polyclonal anti-Pdx1 1:1000 (abcam) at room 
temperature for 2 hours; followed by the incubation with secondary antibodies 
Fluorescein-5-isothiocyanate (FITC) conjugated AffiniPure Donkey Anti-Rat IgG 
1:200 (Jackson ImmunoResearch), Texas red dye-conjugated AffiniPure Goat Anti-
Rabbit IgG 1:200 (Jackson ImmunoResearch) at room temperature for 30 minutes. 
Then the sections were treated with 4',6-Diamidino-2-Phenylindole, DAPI (Sigma 
Aldrich), diluted 1:10000 in PBS at room temperature for 5 minutes. After each 
incubation the sections were washed in PBS. 
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Slides were mounted with Fluorescent mounting medium (Dako Cytomation). 
The images were Acquired with Zeiss Axioplan2 microscope at different 
magnifications and processed by AxioVision Rel.4.8 program. 
Rat anti E-cadherin has a periplasmatic localization, it is expressed in the 
endodermic tissues such us pancreas, thyroid, lung, intestine.  
Rabbit Polyclonal anti-Pdx1 is a nuclear protein, it has a pancreas specific 
expression.  
FITC is fluorescein isothiocyanate, detected as green signal (Absorption max: 492 
nm; Emission max=520 nm). 
Texas Red, derives from sulforodhamine and is detected as a red signal (Absorption 
max=596 nm; Emission max= 620 nm). 
DAPI (4',6-diamidino-2-phenylindole) label DNA with blue emission.  
 
3. Laser capture microdissection and RNA isolation 
The embryos were equilibrated in the cryostat (-25°C) for 5 minutes and mounted on 
the specific support. They were dissected from right to left (pancreas is localized in 
left side) at 8 μm in thickness. When the central part of lung bud was visualized, 
indicating that the plane of sectioning was close to the midline, sections were 
collected on slides. The first section is collected on a slide destined to 
immunofluorescence analysis, the next three are collected on a slide for the LCM 
technique, and so on. The slides were immediately put on dry-ice and stored at -80°C 
overnight. During sectioning was minimized the room temperature section exposure 
time. 
Before sections dehydration, all surfaces, and instruments were treated with RNase 
Zap (Ambion) for 5 minutes followed by 70% EtOH and 100% EtOH, to eliminate the 
extrinsic RNasees. The other utensils were treated, with RNase Zap for 5 minutes 
followed by two washings with H2O-DEPC (water treated with 0.1% of 
diethylpyrocarbonate, a potent RNase inhibitor) and one washing with 100% EtOH. 
The utensils were keep at 60°C up to use, instead the surfaces and the instruments 
were allow to air dry.  
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In the step of  dehydration, the slides were incubated sequentially in 75% EtOH 
(100% EtOH in ddH2O) for 30 seconds, ddH2O for 30 seconds, 75% EtOH for 30 
seconds, 95% EtOH for 30 seconds, 100% EtOH for 30 seconds and Xylene for 5 
minutes. Allow slides dry for 5 minutes under a hood. Dehydration is crucial to 
stabilize the tissues and to allow the capture.  
Laser capture microdissection (LCM) of dorsal pancreatic buds was performed in a 
maximum time of 60 minutes after dehydration and with a 36% of relative humidity in 
the room [84]. These parameters are important because a high ambient humidity 
could rehydrate the sections and reactivate endogenous RNases and the absorption 
of moisture of the atmosphere seems to cause the degradation of RNA and an LCM 
inefficient. LCM was performed using the PixCell II system (Arcturus) under 20x 
magnification with a laser spot size of 10 μm, laser output power of 100 mW and 
pulse duration of 1.5 ms. The LCM technique is performed by placing a thermoplastic 
film 12 μm above the dehydrated tissue section, this position serves to maintain the 
capture area above the surface of the section, avoiding direct contact. The cells of 
interest are localized with an inverted microscope, and on cells are directed pulses 
generated by an infrared laser at low energy to avoid damaging the tissue and 
therefore cells from which to extract RNA. Dorsal pancreas buds dissected from three 
embryos were captured with one cap. After that, the whole sections without 
pancreatic buds were scraped with a scalpel and collected in a 0,5 ml tube. Then, a 
cell extraction device ExtractSure (Arcturus) is placed on the film, creating a room for 
the extraction buffer. The extraction buffer, pre-heated at 42°C, should be applied to 
the cells immediately after the LCM to stabilize the RNA.  
According to manufacturer's protocol of Pico-Pure RNA isolation kit:  
Dispense 10 μl of Extraction Buffer (XB) on each sample and place a new 0.5 ml 
microcentrifuge tube onto the CapSure-ExtracSure assembly and incubate at 42°C in 
the thermoblock for 30 minutes. Centrifuge the microcentrifuge tube with the 
CapSure-ExtracSure assembly at 800 g for 2 minutes to collect cell extract into the 
same. During the incubation of the samples, the RNA Purification Column needs to 
be pre-conditioned. Pipette 250 μl of Conditioning Buffer (CB) onto the purification 
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column filter membrane. Incubate the RNA Purification Column with Conditioning 
Buffer for 5 minutes at room temperature. Centrifuge the purification column in the 
provided collection tube at 16000 g for 1 minute. After that is possible to proceed with 
the RNA isolation protocol. Pipette 10 μl of 70% EthOH into the cell extract, mix well 
by pipetting up and down and do not centrifuge. Pipette the cell extract and EtOH 
mixture into the preconditioned purification column.  
To bind RNA, centrifuge for 2 minutes at 100 g, immediately followed by a 
centrifugation at 16000 g for 30 seconds to remove flow through. Pipette 100 μL 
Wash Buffer 1 (W1) into the purification column and centrifuge for 1 minute at 8000 
g. At this step DNA may be removed. The DNase treatment utilizing the RNase-Free 
DNase Set (Qiagen). Pipette 5 μL DNase I Stock Solution to 35 μl Buffer RDD 
(provided with RNase-Free DNase Set). Mix by gently inverting. Pipette the 40 μl 
DNase incubation mix directly into the purification column membrane. Incubate at 
room temperature for 15 minutes. Finally pipette 40 μl PicoPure RNA Kit Wash Buffer 
1 (W1) into the purification column membrane. Centrifuge at 8000g for 15 seconds 
and proceed with the RNA isolation protocol. Pipette 100 μl Wash Buffer 2 (W2) into 
the purification column and centrifuge for one minute at 8000 g. Pipette another 100 
μl Wash Buffer 2 (W2) into the purification column and centrifuge for 3 minutes at 
16000 g. Transfer the purification column to a new 0.5 ml microcentrifuge tube 
provided in the kit. Pipette 20 μl of Elution Buffer (EB) directly onto the membrane of 
the purification column (Gently touch the tip of the pipette to the surface of the 
membrane while dispensing the elution buffer to ensure maximum absorption of EB 
into the membrane) and incubate the column for 1 minute at room temperature. 
Centrifuge the column for 1 minute at 1000 g to distribute EB in the column, and then 
spin for 1 minute at 16000 g to elute RNA. The entire sample may be used 
immediately or stored at –80°C until use.  
RNA yields were about 5 ng from 3 dorsal buds. RNA quality and integrity was 
determined by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) 
on RNA Pico Chips (Agilent Technologies).  
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According to manufacturer's protocol:  
Cleaning the electrodes  
Before running assay decontaminate the electrodes through the chip washing for 5 
minutes with 350 μl of RNase Zap. Wash the pins with another chip washing for 2 
minutes with 350 μl of RNase free water. To dry the pins leave the lid open for 2 
minutes.  
Preparing gel matrix  
For the preparation of gel matrix allow all reagents to equilibrate to room temperature 
for 30 minutes. Place 600 μl of RNA 6000 Pico gel matrix (red) into the top receptacle 
of a spin filter and centrifuge for 10 minutes at 4000 rpm (rate is stable for one 
month).  
Preparing the Gel-Dye Mix  
Vortex and spin the tube RNA 6000 Pico dye concentrate (blue). Aliquot 65 μl filtered 
gel (gel matrix) in a tube 0.5 ml. Add 1 μl of RNA 6000 Pico dye concentrate to an 
aliquot of filtered gel (gel matrix), centrifuge for 10 minutes at 13000 rpm  and keep in 
the dark.  
Loading the Gel-Dye Mix  
Denature 1.5 μl of each sample for 2 minutes at 70°C. Take an RNA Pico chip and 
place it on the chamber pressure. Pipette 9 μl of the gel-dye mix at the bottom of the 
well marked G and dispense the gel-dye mix. Set the timer to 30 seconds, make sure 
that the plunger is positioned at 1 ml and then close the chip priming station. Press 
the plunger of the syringe down until it is held the clip. Wait 30 seconds and release 
the clip. Slowly pull back the plunger of the syringe to 1 ml position. Open the 
chamber and pipette another 9 μl gel-dye mix in the other 2 wells G. Pipette 9 μl of 
the RNA 6000 Pico conditioning solution (white) into the well marked CS. Pipette 5 μl 
of RNA 6000 Pico Marker (green) into the 11 sample wells and the well marked with 
a ladder symbols. Load 1 μl of the diluted RNA 6000 Pico ladder into the well marked 
with the ladder symbols and 1 μl of each sample into each of the 11 sample wells. 
Centrifuge 1 minute at 2400 rpm the chip on vortex, and then insert it into the 
machine.  
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Using the software  
The 2100 expert software screen shows that you have inserted a chip and closed the 
lid by displaying the chip icon at the top left of the Instrument context. In the 
Instrument context, select the appropriate Assay about RNA and the type of chip (in 
this case, Pico).  
Click the Start button and wait for the outcome of the run. Assess the integrity of RNA 
through the presence 18s and 28s bands. The Bioanalyzer uses software that 
implements an algorithm of analysis obtaining from each electrophoresis a number, 
the RIN (RNA integrity number), representative of the quality of the sample (1, low 
quality; 10, highest quality). The quality of RNA extracted from cells obtained by LCM 
showed bands 18s and 28s, indicating that there is not deterioration in the quality of 
RNA and a good value of the RIN.  
Three biological replicates with RNA integrity numbers (RIN) higher than 7 were 
considered to obtain labeled sense-strand cDNA  (ss cDNA). 
 
4. RNA amplification, labeling and hybridization  
RNA samples obtained by LCM were amplified with the RiboAmp HS PLUS RNA 
Amplification Kit (Arcturus), for the second cycle of cDNA amplification and hydrolysis 
was used the Ambion WT Expression Kit (Ambion) and finally, to labeling ss cDNA 
was used the Affymetrix GeneChip WT Terminal Labeling Kit (Affymetrix). The 
RiboAmp HS PLUS Kit provides sensitivity in linear amplification of small samples 
and enables the production of microgram quantities of amplified antisense RNA 
(aRNA) from picogram or low nanogram amounts of total RNA. The total RNA input 
recommended for RiboAmp amplification is 500 pg to 5 ng that allow to obtain over 
than 30 μg of aRNA. The success of amplification using the RiboAmp HS PLUS RNA 
Amplification Kit depends on the quality of the source RNA. Integrity is affected by 
exposure to internal and external sources of RNases. The three kits listed above 
generate labeled ss cDNA ready for microarray experiments and other downstream 
analysis methods. RNA amplification and labeling can be illustrated as in figure 
(Fig.5).  
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The RiboAmp HS PLUS RNA Amplification Kit utilizes two rounds of a five-step 
process for linear amplification:  
1. 1st strand synthesis reaction that yields cDNA incorporating a T7 promoter 
sequence;  
2. 2nd strand synthesis reaction utilizing exogenous primers that yields double-
stranded cDNA;  
3. cDNA purification using specially designed MiraCol™ Purification Columns;  
4. In vitro transcription (IVT) utilizing T7 RNA polymerase yields antisense RNA 
(aRNA); 
5. aRNA isolation with the MiraCol Purification Columns.  
 
 
 
 
Fig. 5 Molecular events that occurs during RNA Amplification, Labeling and Hybridization.  
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According to manufacturer's protocol:  
Round 1: first strand cDNA synthesis  
RNA input amount was 4.5 ng. The input samples were prepared with H2O DEPC in 
a final volume of 10 μl in 0.2 ml tubes and put at 4°C. Then add to each sample 1 μl 
of Primer 1 (Grey), titillate and spin. Incubate at 65°C for 5 minutes and then at 4°C 
for 1 minute. At the end spin and put in the cold block (4°C).  
Prepare the first strand synthesis mix. The mix for a single sample is composed of 2 
μl Enhancer (Yellow E), 5 μl 1st strand master mix (Red-1), 1 μl 1st strand enzyme 
mix (Red-2) and 1 μl SuperScript III Enzyme Invitrogen (200 U/μl). Titillate and spin 
the mix and add 9 μl of the mix to each sample. Incubate the samples at 42°C for 1 
hour followed by 4°C for 1 minute. Then spin the samples and put them in the cold 
block.  
Add 2 μl of 1st Strand Nuclease Mix (Gold) to the samples and incubate at 37°C for 
30 minutes, 95°C for 5 minutes and 4°C for 1 minute. Spin the samples and put them 
in the cold block.  
 
Round 1: second strand cDNA synthesis  
Add to the samples 1 μl of Primer 2 (Grey-2), titillate, spin and incubate at 95°C for 2 
minutes followed by 4°C for 2 minutes. Spin the samples and put them in the cold 
block. Prepare the second strand synthesis mix. The mix for a single sample is 
composed of: 29 μl of 2nd strand Master Mix (White-1) and 1 μl of 2nd Strand 
Enzyme Mix (White-2). Titillate and spin the mix and add 30 μl of the mix to each 
sample. Incubate the sample at 25°C for 10 minutes, 37°C for 30 minutes, 70°C for 5 
minutes and 4°C for 2 minutes.  
 
Round 1: cDNA purification  
Incubate the purification column with 250 μl of DNA Binding Buffer (DB) for 5 minutes 
and then centrifuge at 16000 g for 1 minute.  
Add 200 μl of DB to each sample, mix up and down and pipette the whole sample on 
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a column. Centrifuge at 100 g for 2 minutes followed by 10000 g for 1 minute. 
Eliminate the eluted DB.  
Add 250 μl of DNA Wash Buffer to each sample and centrifuge at 16000 x g for 3 
minutes. Put the column on a 0,5 ml tube and add 11 μl of Elution Buffer (DE). 
Incubate at room temperature for 1 minute and then centrifuge at 1000 g for 1 minute 
and 1 minute at 16000 g.  
 
Round one: in vitro transcription  
Prepare the IVT Reaction Mix. The mix for a single sample is composed of: 2 μl of 
IVT Buffer (Blue-1), 6 μl of IVT Master Mix (Blue-2), 2 μl of IVT Enzyme Mix (Blue-3) 
and 2 μl of Enhancer (Yellow-E), titillate and spin the mix. Add 12 μl of the mix to 
each sample and incubate at 42°C for 6 hours and at  4°C for 2 minutes or overnight.  
Add 1 μl of DNase Mix (Blue-4) to each sample, titillate, spin and incubate at 37°C for 
15 minutes and then put the samples on a cold block. Proceed immediately with the 
aRNA purification.  
 
Round one: aRNA purification  
Incubate the purification column with 250 μl of RNA Binding Buffer (RB) for 5 minutes 
at room temperature and then centrifuge at 16000  g for 1 minute. Add 120 μl of RB 
to the samples, mix up and down. Pipette the whole sample on the membrane of the 
column and centrifuge at 100 g for 2 minutes followed by 1 minute at 10000 g. 
Eliminate the eluted RB.  
Add 200 μl of RNA Wash Buffer (RW) to each sample and centrifuge at 16000 g for 3 
minutes.  
Put the column on a 0.5 ml tube and add 12 μl of RNA Elution Buffer (RE). Incubate 
at room temperature for 1 minute and then centrifuge at 1000 g for 1 minute and 1 
minute at 16000 g.  
 
Round 2: 1st strand cDNA synthesis  
Add 1 μl of Primer 2 (Grey) to each sample, titillate, spin and incubate at 65°C for 5 
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minutes followed by 4°C for 1 minute. Spin the samples and put them in a cold block. 
Prepare the 1st Strand Synthesis Mix. The mix for a single sample is composed of: 2 
μl of Enhancer (Yellow-E), 5 μl of 1st Strand Master Mix (Red-1), 1 μl of 1st Strand 
Enzyme Mix (Red-), 1 μl of SuperScript III Enzyme. Titillate and spin the mix. Add 9 
μl of the mix to each sample, titillate, spin and incubate at 25°C for 10 minutes, 37°C 
for 1 hour and 4°C for 1 minute.  
 
Round 2: 2nd strand cDNA synthesis  
Add 1 μl of Primer 3 (Grey) to each sample, titillate, spin and incubate at 95°C for 5 
minutes and at 4°C for 2 minutes.  
Prepare the 2nd Strand Synthesis Mix. The mix for a single sample is composed of: 
29 μl of 2nd Strand Master Mix and 1 μl of 2nd Strand Enzyme Mix. Titillate and spin 
the mix. Add 30 μl of the mix to each sample, titillate spin and incubate at 37°C for 30 
minutes, followed by 70°C for 5 minutes and 4°C for 30 minutes.  
 
Round 2: cDNA purification  
Incubate the purification column with 250 μl of DNA Binding Buffer (DB) for 5 minutes 
and then centrifuge at 16000 g for 1 minute.  
Add 200 μl of DB to each sample, mix up and down and pipette the whole sample on 
a column. Centrifuge at 100 g for 2 minutes followed by 10000 g for 1 minute. 
Eliminate the eluted DB.  
Add 250 μl of DNA Wash Buffer to each sample and centrifuge at 16000 g for 3 
minutes. Put the column on a 0.5 ml tube and add 11 μl of Elution Buffer (DE). 
Incubate at room temperature for 1 minute and then centrifuge at 1000 g for 1 minute 
and 1 minute at 16000 g.  
 
Round 2: in vitro transcription  
Prepare the IVT Reaction Mix. The mix for a single sample is composed of: 2 μl of 
IVT Buffer (Blue-1), 6 μl of IVT Master Mix (Blue-2), 2 μl of IVT Enzyme Mix (Blue-3) 
and 2 μl of Enhancer (Yellow-E), titillate and spin the mix. Add 12 μl of the mix to 
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each sample and incubate at 42°C for 6 hours followed by 4°C for 10 minutes.  
Add 1 μl of DNase Mix (Blue-4) to each sample, titillate, spin and incubate at 37°C for 
15 minutes and then put the samples on a cold block. Proceed immediately with the 
aRNA purification.  
 
Round 2: aRNA purification  
Incubate the purification column with 250 μl of RNA Binding Buffer (RB) for 5 minutes 
at room temperature and then centrifuge at 16000 g per 1 minute. Add 120 μl of RB 
to the samples, mix up and down. Pipette the whole sample on the membrane of the 
column and centrifuge at 100 g for 2 minutes followed by 1 minute at 10000 g. 
Eliminate the eluted RB.  
Add 200 μl of RNA Wash Buffer (RW) to each sample and centrifuge at 16000 g for 3 
minutes.  
Put the column on a 0,5 ml tube and add 30 μl of RNA Elution Buffer (RE). Incubate 
at room temperature for 1 minute and then centrifuge at 1000 g for 1 minute and 1 
minute at 16000 g. Store the samples at -80°C overnight.  
At this step samples can be quantized with the Nanodrop instrument.  
Using Ambion WT Expression Kit, sense-strand cDNA is synthesized by the reverse 
transcription of aRNA using random primers. The sense-strand cDNA contains dUTP 
at a fixed ratio relative to dTTP. 10 μg of aRNA is required for 2nd-cycle cDNA 
synthesis.  
 
According to manufacturer's protocol:  
Synthesize 2nd-cycle cDNA  
Prepare aRNA samples in a final volume of 22 μl (in Elution Buffer-Arcturus) in which 
the final amount of aRNA is 10 μg. Add 2 μl of Random Primers and incubate at 70°C 
for 5 minutes, followed by 25°C for 5 minutes and 4°C for 2 minutes.  
Prepare 2nd cycle Master Mix. A mix for a single sample is composed of: 8 μl of 2nd 
Cycle Buffer Mix and 8 μl of 2nd Cycle Enzyme Mix. Titillate and spin the mix. Add 16 
μl of the mix to each sample, titillate, spin and incubate at 25°C for 10 minutes, 42°C 
 
Materials and Methods 
 
 
 
 
37 
for 90 minutes, 70°C for 10 minutes and 4°C for 2 minutes.  
 
Hydrolyze using RNase H  
In this procedure, RNase H degrades the aRNA template leaving single-stranded 
cDNA.  
Add 2 μl of RNase H to each sample and incubate at 37°C for 45 minutes followed by 
95°C for 5 minutes and 4°C for 2 minutes.  
 
Purify 2nd cycle cDNA  
After synthesis, the second-strand cDNA is purified to remove enzymes, salts, and 
unincorporated dNTPs. This step prepares the cDNA for fragmentation and labeling. 
Before beginning the cDNA purification pre-heat the Elution Solution at 58°C for 10 
minutes. Vortex the Nucleic Acid Binding Beads vigorously before use to ensure they 
are fully dispersed. Add to each sample 18 μl of H2O Nuclease-Free, 10 μl of Nucleic 
Acid Binding Beads and 50 μl of Nucleic Acid Buffer Concentrate, for a final volume 
of 60 μl. Transfer each sample to a well of a U-bottom plate. Add 120 μl of 100% 
EtOH to each sample. Pipette up and down 3 times to mix. Gently shake for 2 
minutes on the thermomixer. The cDNA in the sample binds to the Nucleic Acid 
Binding Beads during this incubation. Move the plate to a magnetic stand to capture 
the magnetic beads. When the capture is complete (~5 minutes), the mixture is 
transparent, and the Nucleic Acid Binding Beads form pellets against the magnets in 
the magnetic stand. Carefully aspirate and discard the supernatant without disturbing 
the magnetic beads.  
Add 100 μl of Nucleic Acid Wash Solution to each sample, then shake the samples at 
moderate speed for 1 minute. Move the plate to a magnetic stand to capture the 
Nucleic Acid Binding Beads. Carefully aspirate and discard the supernatant without 
disturbing the Nucleic Acid Binding Beads. Move the plate to a shaker, then shake 
the plate vigorously for 1 minute to evaporate residual ethanol from the beads. Dry 
the solution until no liquid is visible. Elute the purified cDNA from the Nucleic Acid 
Binding Beads by adding 30 μl of pre-heated Elution Solution to each sample. 
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Incubate for 2 minutes at room temperature without shaking. Vigorously shake the 
plate for 3 minutes. Transfer the supernatant, which contains the eluted cDNA, to a 
nuclease-free multiwell plate.  
Using the Affymetrix GeneChip WT Terminal Labeling Kit is possible to fragment, 
label and hybridize the ss cDNA samples on the GeneChip® Mouse Gene 1.0 ST 
Array. The latter is the product in the family of Affymetrix expression arrays offering 
whole-transcript coverage. Each of the 28.853 genes is represented on the array by 
approximately 27 probes spread across the full length of the gene, providing a more 
complete and more accurate picture of gene expression than 3'-based expression 
array designs.  
 
According to manufacturer's protocol:  
ss cDNA fragmentation  
Prepare the ss cDNA in a final volume of 31.2 μl (in H2O RNase Free) in which the 
final amount of ss cDNA is 5l5 μg. Add for each sample 10 μl of H2O RNase free, 48 
μl of 10x cDNA Fragmentation Buffer, 1 μl of UDG (10 U/μl) and 1 μl of APE (1000 
U/μl). Incubate at 37°C for 60 minutes, 93°C for 2 minutes and 4°C for 2 minutes.  
 
ss cDNA labeling  
Add to each sample 12 μl of 5X TdT Buffer, 2 μl of TdT and 1 μl of DNA Labeling 
Reagent (5 mM). Incubate at 37°C for 60 minutes, 70°C for 10 minutes and 4°C for 2 
minutes.  
 
Hybridization  
Each sample was hybridized on a GeneChip® Mouse Gene 1.0 ST Array at 42°C for 
16 hours. Chips were then washed and scanned. 
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5. RNA extraction from embryos or cell cultures 
In order to perform total RNA extraction, the samples were collected and preserved 
in TRIzol (Invitrogen, a monophasic solutions of phenol and guanidine isothiocyanate 
suitable for isolating total RNA, DNA and proteins). After homogenization in TRIzol, 
the samples were treated with 200 µl of chloroform, vortexed for 15 seconds and 
centrifuged at 12000 rpm for 10 minutes; this step is required to remove any trace of 
phenol. In order to precipitate RNA, 500 µl of isopropanol were added to the upper 
phase obtained from the previous step; the samples were incubated for 10 minutes at 
room temperature and centrifuged at 12000 rpm for 10 minutes. After the removal of 
the surnatant, pellets were washed with 1ml of EtOH 75% for 10 minutes at 14000 
rpm and then resuspended in H2O-DEPC. 
 
RNA qualitative control by denaturing agarose gel electrophoresis 
To check the integrity of RNA, each sample was analyzed by electrophoresis on 
agarose gel in denaturing conditions. Agarose was dissolved in H2O-DEPC, then 
MOPS buffer 1x (MOPS buffer 10x: MOPS pH 7.0 200 mM, NaAc 200 mM, EDTA pH 
8.0 10 mM) and of 37% formaldheide (J.T.Baker, the denaturing agent), were added. 
Samples (800 ng) RNA were prepared adding 3 volumes of Loading dye 1x (500µl 
formamide, 100 µl MOPS 10x, 150 µl 37% formaldehyde, 100 µl DYE 10x, 1 µl 
ethidium bromide 10 mg/ml). Samples were denatured at 65°C for 5 minutes and 
loaded on the gel; the electrophoresis was performed at 100 V for about 30 minutes. 
 
6. RT–PCR and quantitative PCR (qPCR) Analyses 
One microgram of RNA was reverse transcribed with QuantiTect Reverse 
Transcription Kit (Qiagen) to obtain cDNA in 200 μl, 5 μl of which (25 ng per reaction) 
was used for qualitative PCR and quantitative PCR analysis.  
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According to manufacturer's protocol:  
Elimination of genomic DNA 
The purified RNA sample is briefly incubated in gDNA Wipeout Buffer at 42°C for 2 
minutes to effectively remove contaminating genomic DNA. In contrast to other 
methods, the RNA sample is then used directly in reverse transcription. 
Reverse transcription 
After genomic DNA elimination, the RNA sample is ready for reverse transcription 
using a master mix prepared from Quantiscript Reverse Transcriptase, Quantiscript 
RT Buffer, and RT Primer Mix. The entire reaction takes place at 42°C for 30 minutes 
and is then inactivated at 95°C for 3 minutes.  
Primers were designed with the Primer 3 program and their sequences are listed in 
Table 1.  
PCR reactions were performed using a commercial Taq DNA polymerase and 
reaction conditions were as follows: initial denaturation at 95°C for 5 minutes, then for 
35 cycles of amplification (30 seconds at denatured temperature of 94°C, followed by 
30 seconds at annealing temperature of 60°C and 30 seconds at extension 
temperature of 72°C) and 10 minutes at 72°C for a final extension. The PCR 
products were analyzed using 2 % agarose gel electrophoresis and visualized by 
staining with ethidium bromide. 
 
Quantitative PCR were performed in duplicate with the power SYBR Green PCR 
Master Mix (Applied Biosystems). The number of cycles of threshold (Ct) was 
measured with 7900 HT System (Applied Biosystems). The Ct is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold as PCR 
amplification proceeds. The data were processed using SDS 2.3 software. The 
distinct dissociation curve of each product was used to determine the specificity of its 
amplification. All quantifications (ΔCt) were normalized with the Gapdh mRNA level, 
then the fold induction was calculated by the ΔΔCt method as described in the 
original paper [85]. 
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Table 1  
Oligo name Sequence 5' to 3' Oligo name Sequence 5' to 3' 
Bex1_Fw ACCTGGTGGTGAGCATCTCT Primer 3_Fw CAATGCTACAGGCTCATGGA 
Bex1_Rv CCTCCTCTAGGTGCACAGTTTT Primer 4_Rv GTGCTGAAGGCGATTAAGT 
Churc1_Fw GAAAACTGCGTGACGATGTG Pdx1_Fw GCTCACCTCCACCACCACCTTC 
Churc1_Rv TTCTCCATCTTCCTCTTTCAGG Pdx1_Rv GGGTCCTCTTGTTTTCCTCGGG 
Fat3_Fw ACTGCCCATGATGAGGATTC Prdxdd1_Fw TGCGGGCTGAGTTAGAACA 
Fat3_Rv GGTGGAATAGAGAGGGACCAC Prdxdd1_Rv_iso1 TTTTGTTTGTGGCACAAGCG 
Foxa2_Fw CTGGGAGCCGTGAAGATGGAAG 
Prdxdd1_Rv_iso1_ 
iso2 
CCCAACTCCTAACTGCTTGC 
Foxa2_Rv TCCAGCGCCCACATAGGATG Pyy_Fw GTCGCAATGCTGCTAATCCT 
Gapdh_Fw AATGGTGAAGGTCGGTGTG Pyy_Rv GTCGCTGTCGTCTGTGAAGA 
Gapdh_Rv GAAGATGGTGATGGGCTTCC Rbm39_Fw AACGGCCATGAAGAACGTAG 
Gcg_Fw GAAGACAAACGCCACTCACA Rbm39_Rv GGCCTCGGAATCTTCTATCC 
Gcg_Rv CTGGCCCTCCAAGTAAGAACT Rnf160_Fw CTGTGATGTGGTCCATAGCTTC 
Ghrelin_Fw TCATCTGTCCTCACCACCAA Rnf160_Rv TCCTTCAGCCACAGAACAGA 
Ghrelin_Rv GCTTGTCCTCTGTCCTCTGG Secretin_Fw AGGACCCCAAGACACTCAGA 
Hnf6_Fw CAAAGAGGTGGCGCAGCGTATC Secretin_Rev GGCAGAAGCCAGTCCTGTAG 
Hnf6_Rv GCTCTTTCCGTTTGCAGGCTG Slc10a4_Fw TGCTGTCCTGGTGGAAATCT 
Nanog_Fw 
AACCAGTGGTTGAAGACTAGCAATG
GTC 
Slc10a4_Rv ACGCCTAGCCCAATAGGAAT 
Nanog_Rv TTCCAGATGCGTTCACCAGATAGC Slc2a1_Fw ACTGGGCAAGTCCTTTGAGA 
Nepn_Fw AACCTCTGTGTTGGACAATGC Slc2a1_Rv GGCTGGGATGAAGATGACAC 
Nepn_Probe _Fw TACATGAGCATGGAGAACAACC Sox17_Fw GCCGATGAACGCCTTTATGGTG 
Nepn_Probe_Rv_SP6 
GCGATTTAGGTGACACTATAGCTGG
CTCGTAGGAGACTGCAA 
Sox17_Rv CATGCGCTTCACCTGCTTGC 
Nepn_RV TCAGAGTTTTGAAGGTGTCATTTT Tff3_Fw CCTGTGCAGTGGTCCTGAA 
Nkx6.1_Fw ACTTGGCAGGACCAGAGAGA Tff3_Probe_Fw GGATAGCTGCAGATTACGTTGGCC 
 
Nkx6.1_Rv 
 
 
AGAGTTCGGGTCCAGAGGTT 
 
 
Tff3_Probe_Rv_SP6 
 
CGATTTAGGTGACACTATAGAGCAATC
AGATCAGCCTTGTGTTG 
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Oligo name 
 
        Sequence 5' to 3' 
 
 
Oligo name 
 
Sequence 5' to 3' 
Oct4_Fw CCGTGTGAGGTGGAGTCTGGAGAC Tff3_Rv CAGGGCACATTTGGGATACT 
Oct4_Rv CGCCGGTTACAGAACCATACTCG Tmem50b_Fw GGCCGGAGTGTGAGTGTATT 
Pcbd1_Fw AGGCCGAGATGCTATCTTCA Tmem50b_Rv ATAGCTGTCACCTCGCACCT 
Pcbd1_Rv CACATTCATGGGTGCTCAAG 
 Primer 1_Fw 
CACTATTGCCAGTCAATACAAGTCT
ACGAG 
Primer 2_Rv CACAACGGGTTCTTCTGTTAGTCC 
 
7. In situ Hybridization  
Digoxigenin labeled RNA probes  
Templates for riboprobes were generated by PCR from cDNA obtained by reverse 
transcription of mRNA from E10.5 mouse embryos using forward and reverse primers 
extended at their 5′ ends with either SP6 promoter sequences 
(CGATTTAGGTGACACTATAGA). The resulting PCR products were resolved on 
agarose gels and desired bands excised and puriﬁed using the QIAGEN gel 
extraction kit (QIAGEN). The purified products were used to obtain a new 
amplification, in this way the products can be puriﬁed using QIAquick PCR 
puriﬁcation kit (QIAGEN), analyzed on an agarose gel.  
Digoxygenin labeled riboprobes were generated by in vitro transcription using DIG-
labeling RNA kit (Roche); in each reaction the follow reagents were added: 
 
 
Template DNA                                                        0.5 µg 
RNA labeling mixture (DIG)                                       2 µl 
10 x transcription buffer                                             2 µl 
RNase inhibitor (40 U/µl)                                        0.5 µl 
RNA polymerase (SP6 20 U/µl)                                2 µl 
Adjust with DEPC-treated water to total                  20 µl 
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The reactions were mixed gently, briefly centrifuged and incubated for 2 hours at 
37°C. After the incubation with 2 µl of DNase I (2 U/µl)  at 37°C for 15 minutes, the 
reaction was stopped with 50 µl of STE and purified in equilibrate Quick Spin 
Columns (Roche)  at 1000 g for 4 minutes.  
To check the integrity of RNA probes, each sample was analyzed by electrophoresis 
on agarose gel in denaturing conditions. 
 
Hybridization 
E10.5 embryos of wild-type C57/Bl6 mice were ﬁxated in  4 % PFA,  cryoprotected in 
30% sucrose, embedded in OCT and stored at - 80°C. Frozen sections (10μm) were 
collected on Superfrost slides (Mentzel Gläser). In situ hybridization of frozen 
sections was performed following the protocol previously described [86]. Briefly, 
sections were fixed in 4% PFA, washed in PBS and treated with 1 µg/ml of 
Proteinase K  (PK) in PBS for 10 minutes at room temperature. After pre-treatment 
with PK, sections were washed in PBS and subjected to acetylation step using 0.25% 
Acetic Anhydride in 1M Triethanolamine-HCl for 10 minutes. 
Thereafter, slides were hybridized over night (50% Formamide; 5x SSC, pH 4.5; 50 
µg/ml yeast tRNA; 1% SDS; 50 µg/ml Heparin) using a probe concentration of 0.5-1 
µg/ml at 68°C.  
For the detection of hybridization, sections were incubated with anti-digoxigenin 
alkaline phosphatase-conjugated Fab fragments (Roche) at 1:4000 dilution. Staining 
was development according to probe-signal, with NBT/BCIP (Roche). Finally, slides 
were fixed in 4% PFA - 0.2% gluteraldehyde and mounted in Dako Glycerol Mounting 
Medium (DakoCytomation) . 
Images were obtained using an Axioplan2 microscope equipped with an Axiocam 
digital camera (Zeiss). Images were processed using the Axion Vision software and 
Image J software. 
 
8. ES cell culture and differentiation 
JM8A cell line are considered feeder independent. These cells are derived from 
C57BL/6N mice and the Agouti allele has been modified to correct the black 
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mutation. Mice derived from these cells will have Agouti coat color and are 
heterozygous for the Agouti allele (A/a). The Nepn mouse strain used for this 
research project was created from ES cell clone EPD0686_5_C01 obtained from 
Komp Repository and generated by the Wellcome Trust Sanger Institute (Fig.6). This 
gene has 2 wild type transcripts, of which 2 are protein-coding. Following removal of 
the floxed region, 2 transcripts are predicted to produce a truncated protein product 
of which 0 may be subject to non-sense mediated decay (NMD).  
 
 
Fig.6 Strategy of homolog ricombination to obtain  ES cell clones with conditional potential. 
 
 
mESCs were cultured at 37°C in a 5% CO2 atmosphere on 0,1% gelatine in ES 
medium composed of Knockout DMEM high glucose (Gibco) supplemented with 15% 
fetal bovine serum (Gibco), 0.1 mM 2(β)-Mercaptoethanol (Sigma), 1mM non-
essential amino acids (Gibco), 2 mM glutamine (Gibco), and 1000 units/ml leukemia 
inhibitory factor (Millipore). Culture media was changed every day and cultures 
passaged every two days. 
 
For differentiation, 1 million of mESCs were plated in 35 mm dishes, as a feeder free 
monolayer. The differentiation medium consists of the in DMEM Low Glucose (Gibco) 
supplemented with 5% fetal bovine serum, 0.1 mM 2(β)-Mercaptoethanol, 1mM non-
essential amino acids, 2 mM glutamine, depleted of LIF, overlayed with 200 μg/ml 
Matrigel (BD Biosciences) and treated with various factors sequentially. 
These factors included Activin A (50 ng/ml, R&D Systems),  all trans retinoic acid 
(RA, 10 μM, Sigma), fibroblast growth factor 10 (Fgf10, 10 ng/ml, R&D Systems), 
Cyclopamine (CYC, 10 μM, Sigma), N-N-(3,5-difluorophenacetyl)-L-
alanylsphenylglycinet-butylesterm (DAPT, 5 μM, Sigma).  Medium was changed 
every two days. 
 
Materials and Methods 
 
 
 
 
45 
 
9. DNA genomic extraction 
The lysis buffer (50mM Tris Hcl pH 8.5, 25 mM EDTA, 1% SDS, 1M NaCl, 1mg/ml 
Proteinase K) was added in 60 mm dishe of cell culture. Digestion is complete after 4 
hours at 60°C with agitation (1000 rpm). The sample was centifuged, at full speed at 
4°C for 10 minutes, after adding 250 μl of NaCl 6M and 1 ml of Isopropanol. The 
pellet was washed with 1 ml of cold 70% EtOH, then dried at room temperature. 
Finally suspended in 100 μl of MilliQ water on a mixer and then store at 4°C. 
 
10. -galactosidase staining 
Cells were fixed with a fixation solution (formaldehyde 37%, glutaraldehyde 25% in 
PBS) for 2 minutes, then washed with PBS and incubated overnight with a PBS 
solution containing Potassium ferro-cyanide (5 mM), Potassium ferri-cyanide (5mM); 
MgCl2 (2 mM) and X-Gal (1 mg/ml) at 37°C. 
 
11. Southern Blot 
Restriction digestion of genomic DNA 
40 µg genomic DNA was digested in 300 µl total volume with 5 units restriction 
enzyme (SacII and AccI, Biolabs)  per µg DNA at 37°C overnight.  
The digestion was purified adding the same volume of 
Phenol:Chloroform:Isoamylalcohol solution and then centrifuged. In the surnatant 
were added 0.1 volume NaAc 3M pH 5.2 and 2.5 volumes ice-cold 100% EtOH, 
precipitated at -20°C for 2 hours. After 20 minutes of centrifugation, pellet was 
washed with 1 ml of cold 70% EtOH, then dried at room temperature. Finally 
suspended in 30 μl of MilliQ water on a mixer. 
 
Agarose gel electrophoresis and transfer to Nylon membrane 
The digested samples were runned on a 0.8% agarose gel without Ethidium 
Bromide, and transferred to a nylon membrane as described previously [88]. Briefly, 
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taking picture of agarose gel and lined up with the phoshorescent ruler along side it, 
in this way can be later estimate the size of  interest band on nylon membrane. 
The next step of depurination is necessary for transfer of the DNA out of the gel, so it 
was placed in 0.2 N HCl for ~ 30 minutes. 
To neutralize, the gel was placed in transfer buffer (0.4M NaOH, 1M NaCl) for 15 
minutes two times. To transfer the DNA onto a nylon membrane overnight, was 
prepared a large dish filled with transfer buffer and  glass plate on top of it to rest the 
gel. Two pieces of wick- blotting paper were cut to the width of the gel and length 
such that the wick is in contact with the bottom of the dish. Wet the wick with transfer 
buffer and smooth out the bubbles gently with a glass pipette. From the bottom to the 
top, the disposition is as follows: 
Agarose gel, turned upside down, with a nick in the bottom right hand corner for 
orientation. 
Wet Hybond N+ nylon membrane cut to the exact size of the gel, with a nick in the 
corner for orientation.  
Two pieces of wet blotting paper cut to size of the gel, and other 30 on top. 
Glass plate and additional weight to keep blot in place. 
 
Hybridization 
A 514-bp Neomicin  probe was ampliﬁed on NeoR with primers Neo-Probe-Fw (5'-
GACCGACCTGTCCGGTGCCCTGAATGAACT-3') and Neo-Probe-Rev (5'-
TATGTCCTGATAGCGGTCCGCCACACCCAG-3'). Hybridization with this probe 
revealed a 11.8-kb band from the targeted locus.  
Taking off the gel and membrane together, can be marked the wells with a pencil. 
After fixation of DNA on membrane with Stratalinker, the filter can be prehybridized in 
Hybridization Buffer (HB, Maleic Acid 1x and Blocking Reagent-Roche) at 55°C for at 
least 30 minutes, and then hybridize adding the probe in HB at 55°C overnight. 
Detection  
To detect the bands of interest, the membrane was washed with SSC 0.2x and 0.1 % 
SDS at 68°C two times for 15 minutes each. After pre-blocking, the membrane was 
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placed with Anti-Digoxigenin-AP-Fab (Roche). The signal was developed with CDP-
Star (Roche) according to manufacturer's instructions. 
 
Results 
 
 
 
 
48 
Results 
 
1. Capture of dorsal pancreas bud by LCM 
In order to dissect the dorsal pancreatic bud at E10.5, and considering the small size 
of the organ at this stage, it was necessary to proceed with LCM.  
To identify the structure of pancreas at E10.5, we performed immunofluorescence 
experiments using two genes as markers: E-cadherin and Pdx1.  E-cadherin is 
expressed in endodermic tissues as pancreas, intestine, lung, thyroid, and Pdx1 is 
specific of pancreas. The localization of Pdx1 protein is nuclear, while E-Cadherin 
localizes at periplasmatic level. 
In particular, we progressively collected the 10 μm sections to perform both bud 
localization through immunofluorescence, and bud microdissection through LCM; 
while in the last case sections were stored in dry ice during the cutting, for 
immunofluorescence we optimized a protocol on the other sections (Fig.9). The 
immunofluorescence protocol has been developed considering that the embryos 
have been included after treatment with sucrose, without any fixtation in 
paraformaldehyde.  Because of the restricted number of sections in which the 
pancreas dorsal bud is distinguishable, we referred to the progression of  branchial 
arches, to define the starting and the ending point of pancreas containing sections 
(Fig.7). In particular, the ventral pancreas bud appears when the third branchial arch 
disappears; in the same sections the right lung and thyroid buds appear; while the 
dorsal pancreatic bud appears when the second branchial arch, thyroid bud and 
trachea disappear. In the following sections the dorsal pancreatic bud is present until 
the second branchial arches and left lung bud reappear. Using this methodology we 
tightly estimated the section coordinates and thickness of several endoderm buds. 
The thickness in which is present the entire pancreatic structure is about 140 µm, so 
we can collect 14 sections of 10 µm. In fact, we find sections only with the dorsal 
pancreas bud or only the ventral pancreas bud. Then, there are sections in which 
both buds are present; near the ventral bud we identify also the gall bladder (Fig.8). 
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Moreover, it was possible to select the sections even before the dehydration allowing 
to reduce the time of exposure of the same to environmental temperature. Following 
the microdissection of dorsal pancreatic buds (DPB), the same sections without 
dorsal pancreatic buds (SwDPB) were collected in order to compare the gene 
expression profile versus the developing pancreatic bud. 
 
 
       Fig. 7 Progression of branchial arches by E-cadherin staining. 
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   Fig. 8 Progression of pancreatic structure. DPB (dorsal pancreas bud), VPB (ventral pancreas  
bud), GB (gall bladder). 
 
 
Fig. 9 The first panel shows  the immunofluorescence of  dorsal pancreas bud, the second panel 
shows the next section after dehydration and the third panel shows the sections after capture in which 
there isn’t dorsal pancreas bud. DPB  (dorsal pancreas bud). 
 
2. Global gene expression profile of dorsal pancreatic bud 
DPB cells of a single embryo are insufficient to obtain the amount of RNA necessary 
to perform the hybridization to microarrays. For this reason, we pooled pancreatic 
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buds of three embryos belonging to three different litters. In this way, we can 
increase the amount of RNA, but also reduce the biological variability. 
Considering that the amount of RNA obtained from pancreatic buds is from 200 pg to 
1.5 ng, we used to linearly amplify the amount of RNA necessary for the following 
assay. 
The overall integrity of RNA isolated with the protocol provided by Arcturus was 
determined by capillary electrophoresis on Bioanalyzer 2100 (Agilent). After several 
experiments, we obtained a RIN between 6.0 and 8.4. The quality of RNA extracted 
from cells obtained by LCM showed 18s and 28s bands, indicating that there was no 
deterioration of RNA. 
Therefore, the samples were selected considering the parameter of RIN and 
concentration, in order to have samples qualitatively and quantitatively similar 
(Fig.10). 
Subsequently, we performed the linear amplification of the same samples following 
the instructions of the RiboAmp HS RNA Amplification Kits (Arcturus), so as to 
amplify the RNA up to 30 µg maintaining the original representation of the mRNA. 
The linear amplification allows us to appreciate the difference in gene expression. 
10 µg of aRNA (antisense RNA) were used to obtain ss cDNA, necessary for 
hybridization to GeneChip Mouse Gene 1.0 ST Array - Affymetrix. In order to have 
the biological and technical triplicate, three samples of DPB and three samples of 
SwDPB  were amplified and hybridized to six different chips.  
 
 
Fig.10 RNA runs on Agilent Pico LabChip 
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To ﬁnd specific genes during pancreas development, we compared the expression 
level of each transcript in DPB with that in the SwDPB and sorted out transcripts with 
an expression level, in DPB, at least 1.2-fold higher than that in the whole embryo. 
By this procedure we detected 162 genes enriched in the DPB.  
Considering that the entire embryo is a mixture of all three germ layers, with this 
approach, we can ﬁnd an enrichment of general epithelial determinants in addition to 
organ speciﬁc transcripts. 
 
 
To validate the results of the 
analysis we considered genes with 
fold change (FC) greater than 1.6 
as shown in the panel. 
 
In particular, we confirmed by 
qPCR the expression of both 
specific pancreatic markers known 
at E10.5 as Pyy, Gcg, Sct, Ghrl, 
and the expression of markers 
unknown as Bex1, Nepn, Pcbd1, 
Prdxdd1, Rnf160, Slc2a1, Tff3 
(Fig. 12).  
 
 
 
 
 
 
 
Fig.11 Expression heatmap showing 
representative genes of DPB. 
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          Fig.12 Validation of candidates by qPCR 
 
3. Characterization of Nepn expression in the early stages of 
pancreas development 
By RT-PCR, we selected Nepn (Nephrocan, Leucine-rich repeats), Prdxdd1 (prolyl-
tRNA synthetase associated domain-containing protein) and Tff3 (Trefoil Factor 3, 
cysteine-rich domain) as specific and exclusive candidates of the pancreas. The 
result was confirmed by in situ hybridization for Nepn and Tff3, while for Prdxdd1 was 
not possible to discriminate the isoform 1 (pancreas specific) from the isoform 2 for 
the high nucleotide identity percentage. The expression level during mouse 
embryogenesis was examined by in situ hybridization using specific riboprobe 
labeled with digoxigenin on sagittal sections from E9.5 to E12.5. We show in the 
panel of figure 14 that the expression of Nepn changed during embryonic 
development, in fact, at E9.5 and E10.5 we noted high expression levels that were 
reduced at E11.5, until E12.5 in which it was not expressed. Tff3 developed a very 
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weak signal, this did not allow us to characterize very well this gene during early 
pancreas development (data not shown). 
 
 
    Fig.13 Validation of candidates by RT-PCR. 
 
 
Fig.14 Validation of Nepn on developing pancreas by in situ hybridization, magnification 20x.
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4. Differentiation of mESCs towards pancreatic lineage in vitro 
In our study, we optimized the protocol  to differentiate mESCs into the 
pancreatic progenitors, following the patterning of definitive endoderm and 
posterior foregut endoderm. 
To achieve a high efficiency of directed differentiation, we induced ESCs in a 
monolayer format to minimize unwanted spontaneous differentiation [89]. In a 
low glucose environment a high concentration of Activin A promoted mESCs to 
give rise effectively to DE (definitive endoderm), marked by the expression of 
Sox17 and Foxa2. Sox17 plays a determinant role in the formation of DE cells 
while Foxa2 marks the anterior primitive streak from which the DE emerges. 
Simultaneously, the expression of undifferentiated mESC pluripotent marker 
genes Nanog and Oct4/Pou5f1 was down-regulated.  
To induce the DE to give rise to PF (posterior foregut) cells, Activin A was 
removed from the culture medium and RA in combination with Fgf10 were 
added. At day 8, the expression of the gut tube marker gene Hnf6 and Pdx1  
was detected.  
In order to differentiate the PF into PP (pancreatic progenitor) cells, CYC, a 
known factor for pancreas specification  and the γ secretase (a component of 
the Notch pathway) inhibitor DAPT were examined in combination with RA. 
Indeed at day 12, a group of PP marker genes including Ptf1a and Nkx6.1 was 
expressed (Fig.15). 
 
 
Fig.15 Validation of positive markers during differentiation by  RT-PCR, rappresentative 
steps of differention at day 4, 8 and 12.  
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To verify if our candidate genes were expressed during differentiaiton, we 
performed qPCR for Bex1, Nepn, Pcbd1, Prdxdd1, Rnf160, Slc2a1, Tff3. 
Four genes (Bex1, Nepn, Pcbd1, Prdxdd1) are up-regulated at day 8 
compared to day 4 during differentiation of mESCs towards posterior foregut 
endoderm; the enrichment of our candidates is emphasized further at day 12.             
 
 
 
Fig.16 The histogram shows the expression of Bex1, Nepn, Pcbd1, Prdxdd1, Rnf160, 
Slc2a1  and Tff3 during differentiation of mESCs  towards pancreatic progenitors at day 4, 
day 8 and day 12. 
 
We have a cell line in which two loxP sites were introduced at the sides of 
Nepn Exon 2 by homologous recombination, in this way has been interrupted 
the transcription of Nepn on first exon to obtain a truncated protein. The 
knockout first allele is initially a non-expressive form, but can be converted to a 
conditional allele via Flp recombination. The correct DNA recombination was 
confirmed on 5’ arm by PCR and on 3’ arm by Southern blot. For PCR, we 
used the Primer 1 designed externally to the arm 5' and the Primer 2 designed 
internally to the region of recombination. For southern blot, we used the 
restriction enzymes SacII and AccI to digest genomic fragment between the 
neomycin resistance (NeoR) and Nepn Exon 3. The fragment length of about 
10 Kb was detected with NeoR probe (Table 1 - Fig. 17).  
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As shown in the panel below, using Nepn+/- cell line the presence of the 
splicing acceptor site and the IRES sequence allows the transcription of Exon 
1 and lacZ. Using a system that induces the expression of Nepn in ES cells, 
such as treatment with RA, we showed the expression on both the wild-type 
allele and the recombinant allele, so the expression of lacZ is correlated with 
the expression of Nepn. This was confirmed by PCR using the Primer 3  
designed on exon 1 and the Primer 4 designed on the LacZ gene, and the 
translation of beta-galactosidase was confirmed by the assay of beta-
galactosidase (Table 1 - Fig. 18).  
In this way we could characterize Nepn-positive in the heterozygous cell line 
after induction of differentiation. 
 
 
 
      Fig.17 Assesment of the 5’ arm by PCR in the left side, and assesment of the 3’ arm by 
southern blot in right side.  
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Fig.18 Expression of Nepn in the cell line Nepn
+/-
.
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Discussion 
 
The pace of development of molecular analytical techniques has been rapid in recent 
years. High throughput methods such as DNA microarrays (“DNA chip technology”) 
and proteomics have enormous potential for revolutionizing the study of molecular 
events associated with physiological and pathological processes. 
Although the technology has become increasingly sophisticated, the accuracy of the 
results obtained is still largely influenced by the selection of appropriate study 
material. 
Tissues are composed of many different cell types, from which it is necessary to 
obtain a pure sample of the cells of interest to acquire meaningful data.  
In this way, the cell specific expression is masked, especially if the cell type of 
interest represents only a small fraction of the entire sample, or if gene expression is 
elevated or suppressed. 
Many techniques have been used in attempts to isolate cell populations, including 
cell culture studies, xenografts, flow cytometry, and various microdissection methods 
such as laser capture microdissection (LCM).  
We considered the cell population that forms the dorsal pancreatic bud at E10.5 
because the aim of our work is based on identification of signature genes involved in 
pancreas development.  
To identify mouse dorsal pancreas bud at the stage E10.5, in which different 
transcription factors are expresses, some unknown and others known as Pdx1 which 
is tissue-specific; Pdx1 was used as a marker of the pancreas in the different 
experiments such as immunofluorescence and LCM. 
We used LCM technology to microdissect these cells from mouse embryos because 
the size of the pancreas, at this stage, is reduced; it’s impossible to dissect surgically.  
To pick out cells of a specific type from the midst of others in the same 
microenviroment is a necessary step for subsequent molecular analysis. LCM 
provides a good way to collect a well defined cell population from a heterogeneous 
and complex tissue organization. The technique reported in this study provides a 
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simple and rapid method that combine excellent tissue morphology with good 
preservation of RNA. 
Microarray require up to 10 µg of cellular RNA, and this is a barrier to the analysis of 
gene expression in low density cell population. To overcome this barrier, we 
performed the linear amplification of mRNA to increase the amount of product 
expression. 
After hybridization to GeneChip Mouse Gene 1.0 ST Array, to find new genes 
expressed during pancreas development we compared the gene expression profile of 
DPB with the gene expression profile of SwDPB. Among the candidate genes we 
focused our attention on Nepn whose spatio-temporal expression was confirmed by 
both qPCR and  in situ hybridization.  
Nephrocan, a novel member of the small leucine-rich repeat protein family, is an 
inhibitor of TGF-beta/Smad signaling. Nepn is expressed in kidney in adult mice, and 
during mouse embryogenesis, the expression was markedly increased at E11.5 
when early kidney development takes place. In the adult mouse kidney, Nepn protein 
was located in distal tubules and collecting ducts [90].  
It was found that Nepn is highly enriched in endoderm by in situ hybridization at 
E8.5–E9.0, Nepn expression level reaches the highest in the midgut. At E9.5, the 
signal is retained but is down-regulated [91]. 
In situ hybridization for Nepn at E14.5 reveals epithelial expression at the pylorus. 
Expression is more robust toward the stomach and is primarily localized to epithelial 
cells closer to the basement  membrane. Nephrocan expression at E16.5 is restricted 
to the base of the developing epithelial glands in stomach and developing villi in 
intestine [92]. 
Nepn expression increases in the Nkx2.2-/- pancreas at E12.5, E13.5, E14.5, and 
E15.5, its expression is detectable in exocrine compartment and overlaps with the 
elastase expression domain. In both wild type and Nkx2.2-/- pancreas the expression 
of gene was already considerably lower at E15.5 when compared to E13.5, although 
even at E15.5, Nepn levels were still significantly higher in the mutant pancreas 
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compared to wild type. This would suggest that Nepn is transiently up-regulated in 
the exocrine pancreas of the Nkx2.2-/- mice [93]. 
In future experiments we will propose the in vivo characterization of Nepn and its 
possible role in the pancreas development. The heterozygous ESCs clone for Nepn 
was microinjected into C57BL/6 blastocysts to generate chimeric mice, in particular 
we generate 3 mice with a high index of chimerism. 
To generate Nepn null mutant mice, heterozygous mutant mice will intercross, and 
the genotypes of 30-day-old offspring will be determined by PCR.  
At the same time, we propose the in vitro characterization of the cell population that 
expresses Nepn during differentiation of mESCs towards the pancreatic progenitors. 
In this case, we would like to sort Nepn-positive cells and define them by RNA-seq 
and qPCR. 
We would like to evaluate the potential of Nepn-/- ES cells to differentiate in 
pancreatic progenitors compared to Nepn+/- cells. 
Whereas preliminary data suggest that Nepn is not expressed in the adult pancreas, 
we will induce damage to the adult pancreas in order to observe whether there is a 
reactivation of the gene by RT-PCR and in situ hybridization. In this case, cells sorted 
will be injected in the damaged organ to verify a possible facilitated regeneration. 
Among our candidates Tff3 and Pcbd1 are enriched during differentiation of mESCs 
towards the pancreatic progenitors. Mice homozygous for Tff3 results in impaired 
intestinal mucosal healing and death from colitis after administration of dextran 
sulfate sodium. Mice show poor epithelial regeneration after injury. 
Mice homozygous for Pcbd1 display hyperphenylalaninemia, are mildly glucose 
intolerant, and are predisposed to cataract formation. 
For this reason we propose in vitro characterization of the cell population that 
expresses them.  
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